Diagnostic indicators of non-cardiovascular chest pain: a systematic review and meta-analysis by Wertli, Maria M et al.
Wertli et al. BMC Medicine 2013, 11:239
http://www.biomedcentral.com/1741-7015/11/239RESEARCH ARTICLE Open AccessDiagnostic indicators of non-cardiovascular chest
pain: a systematic review and meta-analysis
Maria M Wertli*, Katrin B Ruchti, Johann Steurer and Ulrike HeldAbstract
Background: Non-cardiovascular chest pain (NCCP) has a high healthcare cost, but insufficient guidelines exist for
its diagnostic investigation. The objective of the present work was to identify important diagnostic indicators and
their accuracy for specific and non-specific conditions underlying NCCP.
Methods: A systematic review and meta-analysis were performed. In May 2012, six databases were searched. Hand
and bibliography searches were also conducted. Studies evaluating a diagnostic test against a reference test in patients
with NCCP were included. Exclusion criteria were having <30 patients per group, and evaluating diagnostic tests for
acute cardiovascular disease. Diagnostic accuracy is given in likelihood ratios (LR): very good (LR+ >10, LR- <0.1); good
(LR + 5 to 10, LR- 0.1 to 0.2); fair (LR + 2 to 5, LR- 0.2 to 0.5); or poor (LR + 1 to 2, LR- 0.5 to 1). Joined meta-analysis of
the diagnostic test sensitivity and specificity was performed by applying a hierarchical Bayesian model.
Results: Out of 6,316 records, 260 were reviewed in full text, and 28 were included: 20 investigating gastroesophageal
reflux disorders (GERD), 3 musculoskeletal chest pain, and 5 psychiatric conditions. Study quality was good in 15 studies
and moderate in 13. GERD diagnosis was more likely with typical GERD symptoms (LR + 2.70 and 2.75, LR- 0.42 and
0.78) than atypical GERD symptoms (LR + 0.49, LR- 2.71). GERD was also more likely with a positive response to a proton
pump inhibitor (PPI) test (LR + 5.48, 7.13, and 8.56; LR- 0.24, 0.25, and 0.28); the posterior mean sensitivity and specificity
of six studies were 0.89 (95% credible interval, 0.28 to 1) and 0.88 (95% credible interval, 0.26 to 1), respectively. Panic
and anxiety screening scores can identify individuals requiring further testing for anxiety or panic disorders. Clinical find-
ings in musculoskeletal pain either had a fair to moderate LR + and a poor LR- or vice versa.
Conclusions: In patients with NCCP, thorough clinical evaluation of the patient’s history, symptoms, and clinical
findings can indicate the most appropriate diagnostic tests. Treatment response to high-dose PPI treatment provides
important information regarding GERD, and should be considered early. Panic and anxiety disorders are often undiag-
nosed and should be considered in the differential diagnosis of chest pain.Background
In the USA, 6 million patients present to emergency de-
partments with chest pain each year, at an annual cost of
$8 billion [1,2]. In emergency departments, roughly 60%
to 90% of the patients presenting with chest pain have
no underlying cardiovascular disease [3-6]. The propor-
tion of patients with cardiovascular disease may be
higher in specialized units (cardiology emergency depart-
ments, cardiac care units (CCUs), intensive care units
(ICUs)) [7] and lower in the primary care setting
[6,8-10]. Physicians generally assume that patients with* Correspondence: Maria.Wertli@usz.ch
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reproduction in any medium, provided the ornon-cardiovascular chest pain (NCCP) have an excellent
prognosis after ruling out serious diseases. However, pa-
tients with NCCP have a high disease burden; most pa-
tients that seek care for NCCP complain of persisting
symptoms on 4-year follow-up [11]. Furthermore, com-
pared to patients with cardiac pain, patients with non-
cardiac chest pain have a similarly impaired quality of
life and similar numbers of doctor visits [12].
In patients with chest pain, the diagnostic investigation
focuses primarily on cardiovascular disease diagnosis and
is often performed by cardiologists. Upon ruling out car-
diovascular disease, only vague recommendations exist for
further diagnostic investigation, often delaying diagnosis
and appropriate treatment and causing uncertainty for pa-
tients [13]. Limited data are available regarding efficienttd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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studies investigate gastrointestinal diseases, and extensive
provocation testing has been proposed [14]. Some report
that almost half of the patients with NCCP will have
gastrointestinal disorders [12], while others attribute more
than a third of cases to psychiatric disorders, as diagnosed
by the Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition (DSMIV). Referred pain from the
spine and the chest wall are also likely substantial contrib-
utors to NCCP. Information is scarce regarding the appro-
priate diagnostic tests, and their sensitivity and specificity
to discriminate different non-cardiac diseases.
The present systematic review aimed to identify rele-
vant diagnostic tests for patients with NCCP, and to
summarize their positive and negative likelihood ratios
for underlying disease identification.
Methods
Literature search and study selection
This review, conducted in May 2012, followed the QUA-
DAS quality assessment checklist for diagnostic accuracy
studies [15]. We searched six databases (PubMed/Medline,
Biosis/Biological Abstracts (Web of Knowledge), Embase
(OvidSP), INSPEC (Web of Knowledge), PsycInfo (OvidSP),
and Web of Science (Web of Knowledge)) using the follow-
ing search terms as medical subject headings (MeSH) and
other subject headings: thoracic pain, chest pain, non-
cardiac chest pain, atypical chest pain, musculoskeletal
chest pain, esophageal chest, and thoracic spine pain. The
findings were limited to studies investigating ‘diagnosis’,
‘sensitivity and specificity’, ‘sensitivity specificity’, or chest
pain/diagnosis. We applied no limits for study setting or
language; however, one potentially eligible Russian language
article was excluded due to lack of language proficiency
[16]. Appendix 1 depicts three detailed search strategies.
To ensure search completeness, one reviewer (MW)
conducted a hand search of the last 5 years in the four
journals that published most articles about patients with
NCCP (Gastroenterology, Chest, Journal of the American
College of Cardiology and American Journal of Cardi-
ology). Potentially eligible references not retrieved by the
systematic search in the six databases were added. Bibliog-
raphies of included studies were also searched, and poten-
tial eligible references included in the full text review.
Eligibility criteria
Eligible studies included non-screening studies on diag-
nostic accuracy published between 1992 and May 2012.
Inclusion criteria were studies reporting on patients of
18 years and older, seeking care for NCCP. NCCP was
defined as chest pain and cardiac or other vascular dis-
ease was ruled out (that is, cardiovascular disease, aortic
dissection, pulmonary embolism). Exclusion criteria in-
cluded studies with <30 patients per group due toconcerns about sample size [17]. This group size was ar-
bitrarily chosen to exclude studies with the highest risk
of bias, while allowing a comprehensive literature over-
view. Based on the nomogram proposed by Carley et al.
a sample size of more than >150 patients are needed to
accurately assess a diagnostic test [18]; however, with
this sample size cut-off, very few studies (mainly retro-
spective data analyses) would have been eligible.
Study selection, data extraction, and synthesis
Two reviewers (MW and KR) independently screened
6,380 references by title and abstract. Both reviewers inde-
pendently reviewed the full text of 260 studies meeting
the eligibility criteria. Disagreements were discussed and re-
solved by consensus or third party arbitration (JS). Re-
searchers with specific language proficiencies reviewed
non-English language references. When the same study was
included in several publications without change in diagnos-
tic measure, the most recent publication was chosen and
missing information was added from previous publications.
All information regarding the diagnostic test, reference
test, and considered differential diagnosis was extracted
and grouped according to the disease investigated. The
methods used to assess accuracy, sensitivity, and specifi-
city were also extracted.
Quality assessment
Study quality was assessed using the Scottish Intercollegi-
ate Guidelines Network (SIGN) methodology checklist for
diagnostic studies [19]. Overall bias risk and study quality
was rated according to the SIGN recommendations. The
ratings included high quality (++; most criteria fulfilled
and if not fulfilled, the study conclusions are very unlikely
to be altered), moderate quality (+; some criteria fulfilled
and if not fulfilled, the study conclusions are unlikely to be
altered), low quality (−; few or no criteria fulfilled, conclu-
sions likely to be altered). Studies rated as low quality by
both reviewers were excluded from further analysis.
Reference standards and test evaluation
Information about method validity, reliability, practic-
ability and value for clinical practice of the reference and
the standard test was extracted and critically assessed.
When several reference standards were used, all mea-
surements were extracted and used for further analysis.
Statistical analysis
Descriptive statistics were used to summarize findings
across all diagnostic studies. Sensitivity, specificity, posi-
tive and negative predictive values (PPV and NPV, re-
spectively), and positive and negative likelihood ratios (LR
+ and LR-, respectively) were calculated based on a 2 × 2
table (true/false positives, true/false negatives). Pretest
probabilities (prevalence) and the positive and negative
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field contained the value 0, 0.5 was added to each field to
enable value calculation. Test diagnostic accuracy was
assessed as follows [20]: very good (LR+ >10, LR- <0.1);
good (LR + 5 to 10, LR- 0.1 to 0.2); fair (LR + 2 to 5, LR-
0.2 to 0.5); or poor (LR + 1 to 2, LR- 0.5 to 1).
When more than four unbiased studies were available
in clinically similar populations and with comparable
index and reference tests, we performed joined meta-
analysis of the diagnostic test sensitivity and specificity.
We used a hierarchical Bayesian model, as proposed by
Rutter and Gatsonis [21], which accounts for the within-
study and between-study variability and the potentially
imperfect nature of the reference test. The hierarchical
Bayesian model was set up as follows: we assumed J
diagnostic studies in the meta-analysis, with crosstabula-
tion between index test (T1) and reference test (T2)
available for each study, and both tests assumed to be
dichotomous (1 = positive test result, 0 = negative test re-
sult). Each study was assumed to use a different cut-off
value (θj) to define a positive test result. The diagnostic
accuracy of each study was denoted by αj. The model
structure implied a within-study level for study-specific
parameters (θj and αj), and a between-study level for pa-
rameters common among all studies. The model could
theoretically be extended to include study-specific covar-
iates such as percentage of female patients or mean age
to reduce heterogeneity on study level.
Appendix 2 gives details of the model set up and prior
distributions. The results of the Bayesian analysis are sam-
ples from the posterior distribution of the parameters, and
estimates are presented as posterior means (50% quantile),
and lower (2.5% quantile) and upper (97.5% quantile)
bounds, resulting in a 95% credible region. Analyses were
performed using R statistical software and the ‘HSROC’
package [22,23].
Ethics statement
For this study no ethical approval was required. No
protocol was published or registered. All methods were
determined a priori.
Results
Study selection
Figure 1 summarizes the search and inclusion process. Out
of 6380 records, 260 were reviewed in full text, resulting in
exclusion of 232 studies. In total, the analysis included 28
studies. The reasons for exclusion of the 232 studies are
given in Figure 1 and overview of excluded studies reviewed
in full text is give in Appendix 3.
Study characteristics
Table 1 presents the study characteristics, and included
patients. In all, 20 studies (71%) evaluated diagnostictests to identify gastrointestinal disease, mainly gastro-
esophageal reflux disorders (GERD), underlying NCCP.
Musculoskeletal chest pain was investigated in three
studies (11%), and psychiatric conditions in five studies
(18%). Study quality was good in 15 studies (54%) and
moderate in 13 (46%; Appendix 4). No study had to be
excluded because of poor study quality.
Accuracy of symptoms for the diagnosis of GERD
Table 2 summarizes the diagnostic accuracy of the diag-
nostic tests relevant for clinical practice. A comprehen-
sive overview of all evaluated diagnostic tests is provided
in Appendix 5. For diagnosis of GERD, the most com-
mon reference tests (endoscopy and/or 24-h pH-metry)
are reported.
Patients with the main complaint of NCCP were less
likely to have GERD (LR + 0.83, 0.43; LR- 1.13, 1.23)
compared to patients with the main complaint of dys-
phagia (LR + 1.27, 1.16; LR- 0.97, 0.97) or GERD typical
symptoms without chest pain (LR + 1.26, 1.53; LR- 0.93,
0.74) in two studies [25,26]. Two further studies com-
pared the accuracy of NCCP and typical GERD symp-
toms (LR + 2.70 [27], 2.75 [24]; LR- 0.42 [24], 0.78 [27])
with NCCP without GERD symptoms (LR + 0.49; LR-
2.71 [24]) or with NCCP and a history of heart burn
(LR + 2.15; LR- 0.74 [27]).
Accuracy of response to proton pump inhibitor (PPI)
treatment for diagnosis of GERD in NCCP
The effect of treatment with PPI was measured by using a
symptom intensity score (SIS) at baseline and follow-up.
The SIS was calculated by adding the reported daily sever-
ity (mild = 1; moderate = 2; severe = 3; and disabling = 4)
multiplied by the reported daily frequency values obtained
during each week of symptom recording.
Table 2 summarizes the results. Three studies com-
pared the treatment response after high doses of PPI
(rabeprazole [31], lansoprazole [32], omeprazole [33])
for 1 week to placebo. A reduction of the SIS score
of ≥50% was associated with a good LR + and a fair
LR- (LR + 5.48 [33], 7.13 [31], 8.56 [32]; LR- 0.24
[32], 0.25 [33], 0.28 [31]) for the presence or absence
of GERD. The likelihood ratios in the placebo groups
with a reduction of the SIS score of ≥50% were: LR +
0.89 [31], 0.61 [32], 3.04 [33]; LR- 1.03 [31], 1.22
[32], 0.84 [33]. A reduction of the SIS score of ≥65%
resulted in a very good LR + (18.33), and a good LR-
(0.17) [32]. A treatment duration of 4 weeks (lasopra-
zole) resulted in a better LR- (LR + 2.75; LR- 0.13)
[36] when compared to 2 weeks (omeprazole [34], LR
+ 2.7; LR- 0.15).
For joint meta-analysis only studies were considered
with similar study design. Therefore, the active treat-
ment arms of six studies were available for further
Figure 1 Study flow.
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clude study-specific covariates such as the percentage of
female patients or mean age to reduce unexplained het-
erogeneity on study level. However, due to the small
number of studies available for pooling we refrained
from including covariates. Figure 2 shows the summary
receiver operating characteristic (ROC) curve. Consider-
ing the GERD prevalence and the fact that no perfect
reference test is available for GERD (sensitivity of the
24-h pH-metry in endoscopy-negative patients <71%
[57]), the posterior mean sensitivity of what was 0.89
(95% credible interval, 0.28 to 1). The posterior mean of
the specificity was 0.88 (95% credible interval, 0.26 to 1),
respectively.Accuracy of provocation tests for GERD diagnosis
Using a treadmill test during the 24-h pH-metry (refer-
ence test) showed highest LR + for GERD when chest
pain was provoked by exercise (LR + 14.4; LR- 0.79 [39]).
In all patients who underwent treadmill test, a high
number of false negative test results during the treadmill
test were observed.
For joint meta-analysis only studies were considered
with similar study design, again. Five patient groups from
four original studies were included in the analysis [38-41].
Figure 3 shows the summary ROC curve. Considering the
prevalence and imperfect nature of the reference test, pos-
terior mean sensitivity and specificity were 0.53 (95% cred-
ible interval, 0.02 to 1) and 0.93 (95% credible interval,
Table 1 Baseline characteristic of the studies
Author Study design Recruitment Inclusion criteria Exclusion criteria n all (n female),
subgroups
Age, mean
(SD)
Disease
duration
Symptoms suggesting gastroesophageal reflux (GERD)-related non-cardiac chest pain (NCCP)
Kim et al.,
2007 [24]
Cross-sectional,
funding NR
Inpatients with NCCP, referred by a
cardiologist after negative cardiac
evaluation. Tertiary care, Seoul,
Korea.
NCCP was defined when patients
were admitted for chest pain to
the coronary unit for ≥1 episode
of unexplained chest pain/week
for ≥3 months. Cardiac chest pain
was ruled out by
electrocardiogram (ECG), normal
enzymes, negative treadmill
exercise testing, normal or
insignificant ECG changes after
intravenous ergonovine injection
in coronary angiograms.
Severe liver, lung, renal or
hematological disorders. History of
peptic ulcer or gastrointestinal (GI)
surgery, connective tissue disorder
and chest pain originating in a
musculoskeletal disorder.
58 (female 37),
NCCP with GERD
symptoms (sy) 24,
NCCP without
GERD sy 34
54.6 (10.4) 17%
<6 months,
17% 6 to
12 months,
51% 1 to
5 years, 16%
>5 years
Hong et al.,
2005 [25]
Retrospective data
analysis, funding NR
Patients with a clinical suspicion of
esophageal motility abnormalities
and pathological acid exposure
within 1 month were included in
this analysis. Tertiary care, Seoul,
Korea.
Patients with suspicion of
esophageal motility abnormalities
and pathological acid exposure.
NCCP was defined as recurrent
angina-like or substernal chest
pain believed to be unrelated to
the heart, after comprehensive
evaluation by the cardiologist.
Obstructive lesions, previous
esophageal balloon dilatation,
botulism toxin injection, or anti-
reflux surgery. No complaints asso-
ciated with symptoms centered on
the esophagus. Connective tissue
diseases.
462 (female 269),
dysphagia 53,
NCCP 186, GERD
sy 117
47.6 (10.9) NR
Netzer et al.,
1999 [26]
Retrospective data
analysis, funding NR
First-time referrals to esophageal
function testing laboratory. Tertiary
care, Bern, Switzerland.
First-time referrals to esophageal
function testing laboratory. NCCP
group included all patients
referred for GI testing because of
NCCP. Additional information was
obtained by contacting the
general practitioner (GP) and
interviews.
NR 303 (female 145),
GERD 143,
dysphagia 56,
NCCP 45
50 (15) NR
Mousavi et al.,
2007 [27]
Prospective
observational,
funding NR
Outpatient referral by cardiologist
after non-invasive diagnostic evalu-
ation and exclusion of a cardiac or
other source. Semnan, Iran.
Patients with NCCP referred to the
gastrointestinal clinic. NCCP was
diagnosed when chest pain was
believed to be unrelated to the
heart after an evaluation by a
cardiologist including non-invasive
testing and no apparent other
diagnosis was present.
Non-steroidal anti-inflammatory
drug (NSAID) use, peptic stricture,
duodenal/gastric ulcer. History of
upper GI surgery, scleroderma, dia-
betes mellitus, neuropathy, myop-
athy or functional bowel disorders,
any condition that may affect
lower esophageal sphincter pres-
sure or decrease acid clearance
time.
78 (female 37),
NCCP with GERD
sy. 35, NCCP
without GERD 43
50.4 (2.3) 3 to 30 days
(mean 9.3 ±
4.2 days)
Singh et al.,
1993 [28]
Retrospective data
analysis, funding NR
All consecutive outpatients referred
to Esophageal Laboratory for
evaluation of upper gastrointestinal
complaints. Alabama, USA.
61 patients had NCCP and were
analyzed in comparison to reflux
patients for findings in upper
gastrointestinal endoscopy and
ambulatory 24 h pH monitoring
NR 153 (female 40) NR NR
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Table 1 Baseline characteristic of the studies (Continued)
Ho et al., 1998
[29]
Cross-sectional,
research grant,
National University of
Singapore
Outpatient referral for NCCP to the
gastroenterology service. Tertiary
care, Singapore.
Recurrent NCCP ≥3 months.
Normal cardiac evaluation (non-
obstructed coronary arteries (<50%
diameter narrowing), dobutamine
stress echocardiography, exercise
ECG). Cardiologist evaluation not
cardiac.
No history of esophageal disorder
or esophageal surgery
61 (NR) NR ≥3 months
Lam et al.,
1992 [30]
Cross-sectional,
funding NR
Patients referred to the
gastroenterologist after being
released from a cardiac care unit
(CCU) where they were admitted
with suspected myocardial
infarction but negative cardiac
evaluation. Secondary care,
Haarlem, The Netherlands. Patients
were eligible for the study when a
cardiologist determined the chest
pain to be of non-cardiac origin.
Episode of acute, prolonged
retrosternal chest pain. Cardiac
chest pain was ruled out when no
abnormalities on admission ECG,
negative results on heart enzyme
tests, negative exercise test.
Further cardiac testing (coronary
angiography) was only performed
when considered necessary by the
cardiologist.
Age >80 years, ECG ischemic
alterations on the admission,
arrhythmias, or signs of congestive
heart failure
41 (female 41) 61.4 (range 40
to 75)
Acute
episode of
chest pain
Studies investigating the efficacy and diagnostic value of proton pump inhibitor (PPI) trials in GERD-related NCCP
Dickman et al.,
2005 [31]
Randomized,
controlled trial (RCT),
double-blind, cross-
over, Janssen Pharma-
ceutica und Eisai Inc.
Outpatient referral by a cardiologist
after negative cardiac evaluation.
Tertiary care, Arizona, USA.
NCCP ≥3 episodes/week (angina-
like) for ≥3 months. Normal/
insignificant findings coronary
angiogram, or insufficient
evidence for ischemic heart
disease (IHD) in non-invasive tests.
Severe comorbidity, previous
empirical anti-reflux regimen, his-
tory of peptic ulcer disease or
gastrointestinal surgery
35 (female 12),
GERD + 16 (45.7%),
GERD- 19 (54.3%)
55.6 (10.10) ≥3 months
Bautista et al.
2004 [32]
RCT, double-blind,
crossover, TAP
Pharmaceuticals
Outpatient referral by a cardiologist
after negative cardiac evaluation.
Tertiary care, Arizona, USA.
NCCP ≥3 episodes (angina-like) for
≥3 months. Normal/insignificant
findings coronary angiogram, or
insufficient evidence for IHD in
non-invasive tests.
Severe comorbidity, previous
empirical anti-reflux regimen, his-
tory of peptic ulcer disease or
gastrointestinal surgery
40 (female 9),
placebo 40, GERD
+ 18, GERD- 22
54.4 (2.78) ≥3 months
Fass et al. 1998
[33]
RCT, double-blind,
crossover, Astra-
Merck research grant
Outpatient referral by a cardiologist
after negative cardiac evaluation.
Tertiary care, Arizona, USA.
NCCP ≥3 episodes (angina-like) for
≥3 months. Normal/insignificant
findings coronary angiogram, or
insufficient evidence for IHD in
non-invasive tests.
Previous empirical anti-reflux regi-
men, history of peptic ulcer disease
or gastrointestinal surgery
37 (female 1),
GERD + 23, GERD-
14
58.2 (2.3) ≥3 months
Pandak et al.,
2002 [34]
RCT, double-blind,
crossover, Astra
Zeneca
Patients presented with recurrent
chest pain, whose chest pain was
determined by cardiologist to be
of non-cardiac origin with the aid
of methoxyisobutylisonitrile (MIBI)
testing. Tertiary care, Arizona, USA.
Unexplained recurrent chest pain
determined to be of non-cardiac
origin by a cardiologist and had
negative results on MIBI testing
Previous empirical anti-reflux regi-
men, gastric or duodenal ulcer,
prior gastric surgery, abnormalities
on physical exam or chest x-ray
that would explain the chest pain
42 (female 24),
GERD + 20, GERD-
18
Range 22 to
77
≥6 months
Kim et al.,
2009 [35]
Prospective
observational, Janssen
Pharmaceuticals
Inpatients referred after negative
cardiac examination by
cardiologists to gastroenterology.
Tertiary care, Seoul, Korea.
NCCP was defined when patients
were admitted for chest pain to
the coronary unit for ≥1 episode
of unexplained chest pain/week
for ≥3 months. Cardiac chest pain
was ruled out by ECG, normal
enzymes, negative treadmill
Severe comorbidity, history of
peptic ulcer disease or
gastrointestinal surgery, history of
connective tissue disorder and
chest pain originating from
musculoskeletal disorder
42 (female 17),
GERD + 16, GERD-
26
53.9 (12.8) ≥3 months:
n = 12 3 to
12 months;
n = 23 1 to
5 years;
n = 7
>5 years
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exercise testing, normal or
insignificant ECG changes after
intravenous ergonovine injection
in coronary angiograms.
Xia et al., 2003
[36]
RCT, single blind,
Simon KY Lee
Gastroenterology
Research Fund
Referred by a cardiologist after
negative cardiac evaluation.
Tertiary care, Hong Kong, China.
NCCP ≥12 weeks during last
12 months. Normal coronary
angiograph, chest pain considered
by a cardiologist to be NCCP.
Pathologic endoscopic finding,
previous anti-reflux regimen, appar-
ent heartburn, acid reflux, dyspha-
gia and dyspepsia
68 (female 42),
placebo 32,
lansoprazole 36
58.2 (10.0) ≥12 weeks
Kushnir et al.,
2010 [37]
Retrospective data
analysis, Mentors in
Medicine,
Washington
University, St Louis,
MO, USA
Outpatients referred for ambulatory
pH monitoring for the evaluation
of unexplained chest pain. Tertiary
care, Missouri, USA.
Unexplained chest pain. Cardiac
causes were excluded in all
instances before referral.
Anti-reflux surgery in the past,
chest pain was not the dominant
symptom, pH manometry data
incomplete
98 (female 75) 51.8 (1.1) 7.4 ±
4.1 years
Lacima et al.
2003 [38]
Cross-sectional,
funding NR
Referred by a cardiologist after
negative cardiac evaluation.
Barcelona, Spain.
Normal ECG, cardiac enzymes,
treadmill exercise testing, coronary
angiography and epicardial
coronary arteries or with <25%
narrowing, no ECG changes after
intravenous ergonovine injection
Previous anti-reflux regimen, cal-
cium channel blockers, beta
blockers and/or nitrates were with-
drawn at least 7 days before the
study
120 (female 62),
patients 90,
volunteers 30
57 (27 to 82) NR
Studies investigating the value of provocation tests for the diagnosis of GERD-related NCCP
Cooke et al.,
1994 [39]
Cross-sectional,
funding NR
Patients in whom coronary
angiography was performed for
the diagnosis of new chest pain.
Secondary care, London, UK.
New chest pain and normal
coronary anatomy with exertional
pain as principal complaint
Mitral valve prolapse, left
ventricular hypertrophy, previous
myocardial infarction, abnormalities
of resting wall motion on
echocardiography, pain at rest
only, unable to exercise. Previous
anti-reflux regimen, previous
gastroenterologist assessment.
66 (female 34),
non-cardiovascular
disease (CVD) 50,
CVD 16 (controls)
53 (non-CVD),
CVD 58, range
32 to 72
3.4 years
Bovero et al.,
1993 [40]
Cross-sectional,
funding NR
Patients investigated for chest pain.
Secondary care, Genova, Italy.
Chest pain, no coronaroactive
drugs for ≥5 days. No anti-reflux
regimen ≥3 days.
Chest pain of organic and/or
functional cardiologic origin
(evaluated by: ECG, two ergometry
tests, dynamic ECG, thallium
myocardial scintigraphy under
physical stress or echodypiridamole
test, ergonovine or methyl-
ergometrine test, angiography)
67 (female 43),
pain at rest 46,
exertional pain 21
53 (range 34
to 76)
NR
Romand et al.,
1999 [41]
Cross-sectional,
funding NR
Referred after negative cardiac
evaluation. Secondary care, Lyon,
France.
Normal coronary anatomy, normal
ECG, negative treadmill exercise
Cardiologic origin of symptoms,
history of upper gastrointestinal
surgery, duodenal or gastric ulcer,
peptic stricture or stricture by a
tumor
43 (female 19) 56 (range 31
to 78)
n= 25
<1 year; n = 7
1 to 5 years;
n = 11
>5 years
Abrahao et al.,
2005 [42]
Cross-sectional,
funding NR
Referred by a cardiologist after
negative cardiac evaluation.
Tertiary care, Rio de Janeiro, Brazil.
≥1 episode of NCCP/week, normal
coronary angiogram or with <30%
narrowing
Chronic obstructive lung disease,
asthma, cardiac arrhythmia,
cardiomyopathy, valvular heart
disease
40 (female 32) 54.7 (8.4) Mean
24 months
(range 1 to
360 months)
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Ho et al., 1998
[29]
Cross-sectional,
research grant from
the National
University of
Singapore
Referred for NCCP to the
gastroenterology service, Singapore
Recurrent chest pain of
≥3 months; cardiologists
evaluation normal and symptoms
not cardiac (non-obstructed
coronary arteries (<50% luminal
narrowing), dobutamine stress
echocardiography, exercise ECG)
No history of proven esophageal
disorder or esophageal surgery
80 (female 38) 48 (range 21
to 75)
≥3 months
Eosinophilic esophagitis-related NCCP
Achem et al.,
2011 [43]
Retrospective data
analysis, funding NR
Referred for endoscopic evaluation
of NCCP, who had esophageal
biopsies for suspected eosinophilic
esophagitis. Secondary care,
Florida, USA.
Chest pain suspected of being
esophageal origin after negative
cardiac evaluation (either by non-
invasive stress testing or coronary
angiography)
Dysphagia (if this was the main
reason for endoscopy).
Anticoagulant use.
171 (female 104),
24 (female 7)
eosinophilia, 147
(female 97)
normal histology
59 (24 to 86)
normal
histology, 55
(21 to 81)
eosinophilia
NR
Musculoskeletal NCCP
Stochkendahl
et al., 2012 [44]
Cross-sectional,
Foundation
Chiropractic Research
and Postgraduate
Education,
Government
Patients discharged form an
emergency cardiology department.
Tertiary care, Odense, Denmark.
Acute (<7 days) chest pain primary
complaint. Pain in the thorax and/
or neck. Understand Danish. Age
18 to 75 years, resident of the
Funen County.
Cardiovascular disease, previous
percutaneous coronary
intervention or coronary artery
bypass graft: other definite cause,
inflammatory joint disease, insulin
dependent diabetes, fibromyalgia,
malignant disease, apoplexy,
dementia or unable to cooperate,
major osseous anomaly,
osteoporosis, pregnancy
302 (female 132) 52.5 (11.0) Acute
episode,
<7 days
before
admission
Bosner et al.
2010 [45]
Cross-sectional with
6 months follow-up,
federal Ministry of
Education and Re-
search grant
Consecutive recruitment of all
patients presenting to chest pain
in a GP clinic. An independent
interdisciplinary reference panel
decided about the etiology of
chest pain.
Age >35 years, pain (acute or
chronic) localized between
clavicles and lower costal margins
and anterior to the posterior
axillary lines
Patients whose chest pain had
been investigated already and/or
who came for follow-up for previ-
ously diagnosed chest pain were
excluded
1,212 (female 678),
chest wall
symptom (CWS)
565 (female 330)
All 59 (35 to
93), CWS 58
(35 to 90)
Acute pain
28.4%
Manchikanti et
al., 2002 [46]
Cross-sectional, no
funding
Chronic thoracic pain, managed by
one physician and undergoing
diagnostic medial branch blocks.
Private pain practice, USA.
Pain for ≥6 months. Failure of
conservative management with
physical therapy, chiropractic
management and drug therapy.
Age 18 to 90 years.
No radicular pattern of pain, no
disc herniation on MRI
46 (female 31) 46 (2.2) ≥6 months,
mean 86
(SD 17.2)
months
NCCP related to psychiatric diseases
Kuijpers et al.,
2003 [47]
Cross-sectional,
funding NR
Discharged from the hospitals first-
heart-aid service with a diagnosis
of NCCP received an envelope
Chest pain or palpitation
presenting to first-heart-aid service,
received no cardiac explanation
Dementia, live ≥50 km from the
hospital. Do not speak Dutch.
344 (female 151),
Hospital Anxiety
Depression Scale
(HADS) ≥8: 266
(female 123);
HADS <8: 78
(female 28)
HADS ≥8:
55.81 (13.03);
HADS <8:
60.55 (10.84)
NR
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Table 1 Baseline characteristic of the studies (Continued)
Demiryoguran
et al., 2006 [48]
Cross-sectional,
funding NR
Patients admitted to the ER and
discharged with a diagnosis of
NCCP. Ismir, Turkey.
Cardiac chest pain ruled out.
Normal ECGs and low or stable
levels of cardiac markers.
Unstable vital signs, uncooperative
and disoriented patients.
Established diagnoses.
Documented coronary artery
disease, history of trauma to chest
wall, back or abdomen within the
previous week.
157 (female 89),
HADS <10: 108
(female 55), HADS
>10: 49 (female
34)
41.6 (11.7) NR
Foldes-Busque
et al., 2011 [49]
Cross-sectional,
Groupe
interuniversitaire de
recherche sur les
urgences (GIRU) and
Fonds de Recherche
en Santé du Québec
Emergency department (ED),
Monday to Friday between 8 AM
and 4 PM. Tertiary care, Quebec,
Canada.
Low-risk unexplained chest pain,
≥18 years old. English or French
speaking, normal serial ECG,
normal cardiac enzymes.
Explained chest pain (for example
ischemic, cause identifiable by
radiography). Medical condition
that could invalidate the interview
(for example, psychosis,
intoxication, or cognitive deficit),
any unstable condition, or any
trauma.
507 (NR),
derivation sample
201 (female 101);
validation sample
306 (female 173)
Derivation
condition 54.2
(13.9),
validation
condition 53.3
(14.4)
NR
Fleet et al.
1997 [50]
Cross-sectional, Fonds
de Recherché en
Santé Québec
Consecutive patients presenting to
ambulatory walk in ED, patients
with or without IHD, Québec,
Canada
Complaint of chest pain,
understand French, able to
complete evaluation in the ED
Cognitive impairment, psychotic
state
Derivation sample
180 (female 63),
validation sample
212
Development
57.6 (12.6),
validation 56
(12.2)
NR
Katerndahl et
al., 1997 [51]
Cross-sectional, public
health and service
Establishment of
Departments of
Family Practice
Presented to the GP with a chief
compliant of new-onset chest pain.
Primary care, Texas, USA.
Adults 18 years and older, new-
onset chest pain, only one com-
plaint (chest pain) as well as those
with several symptoms that in-
cluded chest pain
Previous investigation for chest
pain at the practice
51 (NR) 42.6 (14.6) New onset
NR not reported.
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Table 2 Summary of diagnostic accuracy of tests used in non-cardiac chest pain
Author, year
Evaluated test Reference standard Prevalence,% LR+ LR-
Symptoms
Kim et al. [24] NCCP with atypical GERD symptoms Endoscopy (LA classification) and/or 24 h pH-metry
(>4%, pH <4
24 0.49 2.71
Kim et al. [24] NCCP with typical GERD symptoms Same 67 2.75 0.42
Mousavi et al. [27] NCCP with typical GERD symptoms GERD if two tests positive: endoscopy (Hentzel-Dent),
Bernstein test, omeprazole trial
45 2.70 0.78
Mousavi et al. [27] NCCP relieved by antacid Same 45 0.51 3.51
Mousavi et al. [27] NCCP and heartburn in past history Same 45 2.15 0.74
Mousavi et al. [27] NCCP and regurgitation in past history Same 45 2.98 0.61
Hong et al. [25] NCCP Manometry (Specler 2001 criteria) and/or 24 h pH-metry
(>4% pH <4)
43 0.83 1.13
Hong et al. [25] Control: dysphagia Same 45 1.27 0.97
Hong et al. [25] Control: GERD-typical symptoms Same 44 1.26 0.93
Netzer et al. [26] NCCP Manometry and/or 24 h pH-metry (>10.5% pH <4) 84 0.43 1.23
Netzer et al. [26] Control: GERD-typical symptoms Same 84 1.53 0.74
Netzer et al. [26] Control: dysphagia Same 84 1.16 0.97
Proton pump inhibitor (PPI) trial
Dickman et al. [31] Rabeprazole 20 mg twice a day for 1 week SIS ≥50% Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry
(>4.2% pH <4)
46 7.13 0.28
Dickman et al. [31] Placebo for 1 week Same 46 0.89 1.03
Bautista et al. [32] Lansoprazole 60 mg AM, 30 mg PM for 1 week SIS ≥50% Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry
(>4.2% pH <4)
45 8.56 0.24
Bautista et al. [32] Lansoprazole 60 mg AM, 30 mg PM for 1 week SIS ≥65% Same 45 18.33 0.17
Bautista et al. [32] Placebo for 1 week Same 45 0.61 1.22
Fass et al. [33] Omeprazole 40 mg AM, 20 mg PM for 1 week SIS ≥50% Endoscopy (Hentzel-Dent grades) and/or 24 h pH-metry
(>4.2% pH <4)
62 5.48 0.25
Fass et al. [33] Placebo for 1 week Same 62 3.04 0.84
Pandak et al. [34] Omeprazole 40 mg twice a day for 2 weeks SIS ≥50% Endoscopy and/or 24 h pH-metry (>4.2% pH <4) 53 2.70 0.15
Pandak et al. [34] Placebo for 2 weeks SIS ≥50% Same 53 0.30 1.14
Kim et al. [35] NCCP rabeprazole for 1 week SIS ≥50% Endoscopy (LA classification) and/or 24 h pH-metry
(>4.0 pH <4)
38 2.17 0.65
Kim et al. [35] NCCP rabeprazole for 2 weeks SIS ≥50% Same 38 3.02 0.26
Xia et al. [36] Lansoprazole 30 mg once a day for 4 weeks SIS ≥50% 24 h pH-metry (De Meester pH <4, 7.5 s) 33 2.75 0.13
Xia et al. [36] Placebo for 4 weeks SIS ≥50% Same 38 0.95 1.03
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Table 2 Summary of diagnostic accuracy of tests used in non-cardiac chest pain (Continued)
Kushnir et al. [37] High-degree response on PPI (not specified) 24 pH-metry (≥4%, pH <4) 53 1.97 0.38
Provocation test
Cooke et al. [39] NCCP during exertional pH-metry 24 h pH-metry (5.5% pH <4 for 10 s) 38 14.40 0.79
Cooke et al. [39] Control group: CVD with angina: exertional pH-metry Same 19 4.33 0.72
Bovero et al. [40] NCCP with normal ECG during exertional pH-metry 24 h pH-metry (De Meester criteria: >4.5% pH <4)) 69 7.76 0.66
Bovero et al. [40] NCCP at rest: NCCP with normal ECG during exertional pH-metry Same 74 3.88 0.74
Bovero et al. [40] NCCP exertion/mixed: NCCP with normal ECG during exertional pH-metry Same 57 10.00 0.50
Romand et al. [41] NCCP: pH <4 for 10 s during exertional pH-metry 24 h pH-metry (De Meester criteria: >4.5% pH <4)) 23 1.65 0.52
Abrahao et al. [42] NCCP reproducible during balloon distension Endoscopy (Savary-Miller) and/or manometry and/or
pH-metry (De Meester criteria: >4.5% pH <4
88 2.00 0.75
Abrahao et al. [42] NCCP reproducible during Tensilon test Same 88 0.43 1.38
Abrahao et al. [42] NCCP reproducible during Bernstein test Same 88 1.29 0.93
Abrahao et al. [42] Tensilon and Bernstein Test and balloon distension (+ if 1 test +) Same 88 0.95 1.07
Ho et al. [29] NCCP reproducible during Bernstein test 24 h pH-metry (>4% pH <4, 4 s) 23 0.75 1.06
Musculoskeletal disorders
Stochkendahl et al. [44] ≥3 of 5 palpation findings: (1) sitting motion of end-play restriction in
lateral flexion and rotation segment C4 to C7 and Th1 to Th8. (2)
Prone motion joint-play restriction segment Th1 to Th8. (3) Prone
evaluation paraspinal tenderness segment Th1 to Th8. (4) Supine
manual palpation muscular tenderness of 14 points anterior chest
wall. 5) Supine evaluation of tenderness of the costosternal
junctions of costa 2 to 6 and xiphoid process
Diagnosis using a standardized examination protocol: 37 1.52 0.03
(1) A semistructured interview: pain characteristics, lung
and gastrointestinal symptoms, past medical history,
height, weight, cardiovascular risk factors
(2) A general health examination: blood pressure, pulse,
heart and lung stethoscopy, abdominal palpation, neck
auscultation, signs of left ventricular failure, neurological
examination
(3) Manual examination of the muscles and joints (neck,
thoracic spine and thorax): active range of motion,
manual palpation 14 points muscular tenderness of the
anterior chest wall and segmental paraspinal muscles,
motion palpation for joint-play restriction of the thoracic
spine (Th1 to 8), and end play restriction of the cervical
and thoracic spine
Bosner et al. [45] Chest wall symptom (CWS) score: localized muscle tension,
stinging pain, pain reproducible by palpation, absence of cough
Interdisciplinary consensus: cardiologist, GP, research
associate (based on reviewed baseline, follow-up data at
6 weeks and 6 months)
47 1.82 0.20
Cut-off test negative 0 to 1 points
Bosner et al. [45] CWS score: localized muscle tension, stinging pain, pain
reproducible by palpation, absence of cough
Interdisciplinary consensus 47 3.02 0.47
Cut-off test negative 0 to 2 points
Stochkendahl et al. [44] Biomechanical dysfunction (part of the standardized
examination protocol)a
Standardized examination protocol 37 1.58 0.00
Stochkendahl et al. [44] Anterior chest wall tenderness Standardized examination protocol 37 1.39 0.06
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Table 2 Summary of diagnostic accuracy of tests used in non-cardiac chest pain (Continued)
Stochkendahl et al. [44] Angina pectoris (uncertain or negative) Standardized examination protocol 37 1.26 0.12
Stochkendahl et al. [44] Pain worse on movement of torso Standardized examination protocol 37 3.39 0.78
Bosner et al. [45] Pain worse with movement Interdisciplinary consensus 47 2.13 0.75
Stochkendahl et al. [44] Positive/possible belief in pain origin from muscle/joints Standardized examination protocol 37 1.17 0.20
Stochkendahl et al. [44] Pain relief on pain medication Standardized examination protocol 37 3.26 0.83
Bosner et al. [45] Pain reproducible by palpation Interdisciplinary consensus 47 2.08 0.54
Stochkendahl et al. [44] Paraspinal tenderness Standardized examination protocol 37 1.36 0.48
Bosner et al. [45] Localized muscle tension Interdisciplinary consensus 47 2.41 0.52
Stochkendahl et al. [44] Chest pain present now Standardized examination protocol 37 1.35 0.46
Bosner et al. [45] Pain now Interdisciplinary consensus 47 1.15 0.85
Stochkendahl et al. [44] Pain debut not during a meal Standardized examination protocol 37 1.10 0.23
Stochkendahl et al. [44] Sharp pain Standardized examination protocol 37 1.89 0.80
Bosner et al. [45] Stinging pain Interdisciplinary consensus 47 1.87 0.66
Stochkendahl et al. [44] Hard physical exercise at least once a week Standardized examination protocol 37 1.19 0.91
Stochkendahl et al. [44] Pain not provoked during a meal Standardized examination protocol 37 1.09 0.25
Stochkendahl et al. [44] Not sudden debut Standardized examination protocol 37 2.90 0.63
Bosner et al. [45] Pain >24 h Interdisciplinary consensus 47 1.30 0.92
Stochkendahl et al. [44] Age ≤49 years old Standardized examination protocol 37 2.10 0.56
Bosner et al. [45] Pain mostly at noon time Interdisciplinary consensus 47 0.50 1.02
Bosner et al. [45] Cough Interdisciplinary consensus 47 0.28 1.18
Bosner et al. [45] Known IHD Interdisciplinary consensus 47 0.52 1.11
Bosner et al. [45] Pain worse with breathing Interdisciplinary consensus 47 1.28 0.93
Psychiatric diseases
Kuijpers et al. [47] Anxiety subscale of the Hospital Anxiety and Depression Scale
(HADS-A score, cut-off ≥8)
Diagnosis anxiety disorders (Mini Intern nal
Neuropsychiatric Interview (gold standa
58 2.03 0.03
Demiryoguran et al. [48] Chills or hot flushes Anxiety disorder: HADS-A score (cut-off ) 31 4.85 0.81
Demiryoguran et al. [48] Fear of dying Anxiety disorder: HADS-A score (cut-off ) 31 4.04 0.82
Demiryoguran et al. [48] Diaphoresis Anxiety disorder: HADS-A score (cut-off ) 31 3.49 0.69
Demiryoguran et al. [48] Light-headedness, dizziness, faintness Anxiety disorder: HADS-A score (cut-off ) 31 3.03 0.84
Demiryoguran et al. [48] Palpitation Anxiety disorder: HADS-A score (cut-off ) 31 1.54 0.83
Demiryoguran et al. [48] Shortness of breath Anxiety disorder: HADS-A score (cut-off ) 31 1.30 0.92
Demiryoguran et al. [48] Nausea or gastric discomfort Anxiety disorder: HADS-A score (cut-off ) 31 1.98 0.90
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Table 2 Summary of diagnostic accuracy of tests used in non-cardiac chest pain (Continued)
Foldes-Busque et al. [49] The Panic Screening Score (derivation population); does the patient
have a history of anxiety disorders? Please indicate how often this
thought occurs when you are nervous: ‘I will choke to death’. Did
the patient arrive in the ED by ambulance? Please answer the
statement by circling the number that best applies to you: ‘When
I notice my heart beating rapidly, I worry that I might be having
a heart attack’. Sum score 22, A total score ≥6 indicates probable panic.
Panic disorder Diagnosis (structured Anxiety Disorders
Interview Schedule for Diagnostic and Statistical Manual
of Mental Disorders, fourth edition (DSM-IV) (ADIS-IV))
42 3.89 0.44
Foldes-Busque et al. [49] The Panic Screening Score (validation population). Panic disorder diagnosis (structured ADIS-IV) 43 3.44 0.55
Fleet et al. [50] Panic disorder diagnosis: formula including Agoraphobia Cognitions
QA, Mobility Inventory for Agoraphobia, Zone 12 Dermatome
Pain Map, Sensory McGill Pain QA, Gender, Zone 25 (validation
population)
Panic disorder (ADIS-R structured interview by
psychologist)
23 2.60 0.46
Katerndahl et al. [51] GP diagnosis of panic disorder Panic disorder (structured clinical interview of Diagnostic
and Statistical Manual of Mental Disorders, based on
DSM-III-R)
55 0.82 1.02
LR+: >10; LR-: <0.1; good: LR + 5 to 10, LR- 0.1 to 0.2; fair: LR + 2 to 5, LR- 0.2 to 0.5; poor: LR + 1 to 2, LR- 0.5 to 1.
aBiomechanical dysfunction defined as chest pain presumably caused by mechanical joint and muscle dysfunction related to C4 to Th8 somatic structures of the spine and chest wall established by means of joint-play
and/or end-play palpation.
Reference tests are as follows. Endoscopic classification: LA classification: grade A, ≥1 mucosal break ≤5 mm, that does not extend between the tops of two mucosal folds; grade B, ≥1 mucosal break >5 mm long that
does not extend between the tops of two mucosal folds; grade C, ≥1 mucosal break that is continuous between the tops of two or more mucosal folds but which involves <75% of the circumference; grade D, ≥1
mucosal break which involves at least 75% of the esophageal circumference [52]. Savary-Miller system: grade I, single or isolated erosive lesion(s) affecting only one longitudinal fold; grade II multiple erosive lesions,
non-circumferential, affecting more than one longitudinal fold, with or without confluence; grade III, circumferential erosive lesions; grade IV, chronic lesions: ulcer(s), stricture(s) and/or short esophagus. Alone or associ-
ated with lesions of grades 1 to 3; grade V, columnar epithelium in continuity with the Z line, non-circular, star-shaped, or circumferential. Alone or associated with lesions of grades 1 to 4 [53]. Hentzel-Dent grades:
grade 0, no mucosal abnormalities; grade 1, no macroscopic lesions but erythema, hyperemia, or mucosal friability; grade 2, superficial erosions involving <10% of mucosal surface of the last 5 cm of esophageal squa-
mous mucosa; grade 3, superficial erosions or ulceration involving 10% to 50% of the mucosal surface of the last 5 cm of esophageal squamous mucosa; grade 4, deep peptide ulceration anywhere in the esophagus
or confluent erosion of >50% of the mucosal surface of the last 5 cm of esophageal squamous mucosa [54]. pH-metry: De Meester criteria: (1) total number of reflux episodes; (2) number of reflux episodes with pH <4
for more than 5 minutes; (3) duration of the longest episode; (4) percentage total time pH <4; (5) percentage upright time pH <4; and (6) percentage recumbent time pH <4. [55]. Manometry: Spechler criteria is diag-
nosis of ineffective esophageal motility, nutcracker esophagus, spasm, achalasia based on basal lower esophageal sphincter pressure, relaxation, wave progression, distal wave amplitude [56].
24-h pH-metry 24-h pH monitoring, GERD gastroesophageal reflux disease, GP general practitioner, IHD ischemic heart disease, QA questionnaire, Sensory McGill McGill Pain Questionnaire sensory subscale, SIS symptom
index score calculated by adding the reported daily severity (mild = 1; moderate = 2; severe = 3; and disabling = 4) multiplied by the reported daily frequency values during each week).
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Figure 2 Summary receiver operating characteristic (ROC) curve of proton pump inhibitor (PPI) studies.
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test, Bernstein test, or balloon distension test) high num-
bers of false negative results were found [29,42].
Accuracy of patient characteristics for eosinophilic
esophagitis diagnosis
Eosinophilic esophagitis is a rare but important differen-
tial diagnosis for NCCP. In a retrospective analysis the
likelihood for histologically proven eosinophilic esopha-
gitis (reference test) was fair when current GERD symp-
toms were present (LR + 2.36, LR- 0.71 (poor)). Male
gender or the presence of typical endoscopic findings for
eosinophilic esophagitis were associated with a poor LR
+ (1.78) but a very good LR- (0.09) No information was
available about eosinophilia that responds to PPI treat-
ment compared to eosinophilic esophagitis.
Accuracy of clinical signs for musculoskeletal chest pain
diagnosis
In one study in a cardiology emergency department
specific clinical signs or symptoms compared to a
standardized examination protocol showed either fair
LR + and poor LR- (for example, pain worse with
movement of the torso, pain relief on pain medication,
no sudden pain start, age ≤49 years) or a poor LR +
and a very good LR- (for example, anterior chest wall
tenderness, biomechanical dysfunction) [44]. A score
of 3 or more points in a sum score (1 point for each offive palpation findings: restriction in C4 to 7/Th1 to
Th8 when sitting; prone restriction Th1 to 8; para-
spinal tenderness; anterior chest wall tenderness; cost-
osternal junction tenderness) showed an LR + of 1.52
and very good LR- of 0.03. A score of 1 or more points
in a sum score for the diagnosis of a chest wall syn-
drome (CWS) in the GP setting (1 point for each posi-
tive finding: localized muscle tension; stinging pain;
pain reproducible by palpation; absence of cough)
showed a LR + of 1.82 and LR- of 0.20 [45]. A score of
2 or more points in the sum score showed a LR + of
3.02 and LR- of 0.47.
Accuracy of patient characteristics for psychiatric disease
diagnosis
For the diagnosis of an anxiety disorder the anxiety sub-
scale of the Hospital Anxiety and Depression Score
(HADS-A, cut-off ≥8) compared to a neuropsychiatric
interview (reference test) showed a very good LR- (0.03)
and a fair LR + (2.03). In further studies the HADS-A
was used as reference test for the diagnosis of anxiety
disorder. Specific symptoms showed a fair LR + and a
poor LR-: fear of dying (LR + 4.04; LR- 0.82); light-
headedness, dizziness, or faintness (LR + 3.03; LR- 0.84);
diaphoresis (LR + 3.49; LR- 0.69); and chills or hot
flushes (LR + 4.85; LR- 0.81).
For panic disorders a four-item panic screening
score validated in patients presenting to an ER
Figure 3 Summary receiver operating characteristic (ROC) for treadmill test during 24 h pH-metry.
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(0.44 and 0.55) [49]. A combination of different ques-
tionnaires and pain patterns (Agoraphobia Cognitions
Questionnaire; Mobility Inventory for Agoraphobia;
McGill Pain Questionnaire sensory) showed a fair LR
+ (2.6) and fair LR- (0.46) [50]. In patients presenting
to their primary care physician with NCCP the pres-
ence of a panic disorder was rarely diagnosed. Clin-
ician consultations in this setting had poor accuracy
for panic disorder diagnosis (LR + 0.8; LR- 1.02) [51].Discussion
Main findings
The included studies showed that most studies investi-
gated tests for gastroesophageal reflux disease (GERD)
as the underlying disease in non-cardiovascular chest
pain (NCCP). Few studies investigated diagnostic tests
for other illnesses. The diagnostic value of a PPI
treatment test was confirmed, with a ≥50% symptom
reduction under PPI treatment showing posterior sen-
sitivity and specificity of almost 90%. Together with
the favorable adverse effect profile of PPIs, a high
dose (double reference dose, twice daily) can quickly
provide important diagnostic information in patients
with unexplained chest pain. History or presence of
typical GERD-associated symptoms increases the like-
lihood of GERD.Only limited evidence was available for other prevalent
illnesses manifesting with chest pain. Screening tools for
panic and anxiety disorders are valuable for identifying
patients requiring further diagnostic evaluation. The
likelihood for musculoskeletal chest pain increased when
the pain was reproducible or relieved by pain medica-
tion. Among studies investigating musculoskeletal dis-
ease, the major limitation was the lack of a reference test
(‘gold standard’).
Results in light of existing literature
To the best of our knowledge, this is the first system-
atic review summarizing the current evidence on the
accuracy of diagnostic tests in patients with NCCP.
Several non-systematic reviews have suggested various
diagnostic and therapeutic approaches [14,58-61],
often with algorithms focused on gastrointestinal dis-
eases [14,58,59], sometimes recommending extensive
testing, such as provocation tests. Here, we found no
additional value of provocation testing for diagnosing
underlying gastroesophageal conditions, as provoca-
tion tests failed to identify many patients that would
have reflux during a 24-h pH measurement period.
While meta-analyses of PPI treatment studies com-
pared to placebo have been previously conducted
[62,63], compared to this analyses we excluded studies
of poor quality and small sample sizes [64-67]. Our
study is the first to assess study quality and to use a
Wertli et al. BMC Medicine 2013, 11:239 Page 16 of 35
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within-study and between-study variability and the
imperfect nature of the reference test.
Cremonini et al. [62] previously used a bivariate
model, and found a lower pooled sensitivity and spe-
cificity (sensitivity 80% vs 89%, specificity 74% vs
88%) of a positive PPI treatment response for the
diagnosis of GERD. Harbord et al. [68] showed that
the likelihood functions of the two model formula-
tions are algebraically identical in the absence of co-
variates. However, for assessing a summary ROC
curve, the hierarchical Bayesian model is more natural
than the model for pooled sensitivity and specificity
[69]. Without a broadly accepted standard reference
test, it is important to adjust for conditional depend-
ence between multiple tests (index test and reference
test) carried out in the same subjects [69]. The hier-
archical Bayesian model can be adapted to this situ-
ation by introducing covariance terms between the
sensitivities and specificities of the index and refer-
ence tests. A previous simulation study [69] demon-
strated that if a model does not address an imperfect
reference test, bias will be around 0.15 in overall sen-
sitivity and specificity [69]. No systematic review has
examined diagnostic studies of musculoskeletal chest
pain or chest pain as part of a psychiatric disease.
Strengths and limitations
This review comprehensively evaluates the currently
available studies. The search was inclusive, no language
restrictions were applied, and a thorough bibliographic
search was conducted to identify all relevant studies.
The extraction process was performed in accordance
with current guidelines and supported by an experienced
statistician. Potential factors influencing diagnostic test
accuracy were identified by a multidisciplinary team
(an internist, general practitioner, statistician, and
methodologist).
The study was limited by the small number of studies
available for most diseases presenting with NCCP. Fur-
thermore, many studies were only of moderate quality and
most cross-sectional or prospective studies did not meet
the required sample size criterion for reliable estimates of
sensitivity and specificity. Small studies on diagnostic ac-
curacy are often imprecise, with wide confidence intervals,
making it difficult to assess test informativeness [17]. The
lack of a gold standard reference test is another limitation,
which we addressed within the Bayesian model formula-
tion; however, the resulting posterior credible intervals for
overall sensitivity and specificity of the index test are wider
than they would be with a perfect reference test. Further,
NCCP is a collective term with potentially different under-
lying diseases and therefore might present differently.
Diagnostic accuracy in one population with highprevalence for one disease is high might be entirely differ-
ent for another population [70]. Therefore, for most stud-
ies no joint meta-analysis could be conducted and results
have to be interpreted on a single study level within the
context of the study population. We have tried to balance
this by providing a thorough description of the studies’ in-
clusion and exclusion criteria and the study setting. This
will allow readers to judge to whom study results apply. In
studies included in the joint meta-analyses, we intended to
include study-specific covariates such as the percentage of
female or mean age into the Bayesian model. The inclu-
sion of covariates can reduce unexplained heterogeneity.
However, this was due to the small number of studies
available for meta-analysis not feasible.Research implications
Further research should investigate the combined value of
symptoms, clinical findings, and diagnostic tests, including
multidisciplinary research aimed at increasing our know-
ledge about diagnostic processes and making recommenda-
tions for diagnostic tests and treatments in patients with
NCCP. Most patients with chest pain consult primary care
physicians [45], but few studies are performed in this set-
ting. Further research is needed to strengthen the evidence
in a primary care setting. The value of screening question-
naires for panic and anxiety disorders should be further
evaluated and investigated in clinical practice. The use of a
flag system [61], as successfully applied in back and neck
pain, could facilitate the diagnostic process allowing sys-
tematic assessment of first red flags (acute disease requiring
immediate diagnosis and care), then green flags (identifi-
able diseases), and yellow flags (psychological diseases).Implication for practice
Patients with NCCP incur high healthcare costs due to the
extensive and often invasive diagnostic testing, and NCCP’s
impact on quality of life. Early identification of underlying
diseases is essential to avoid delayed treatment and chron-
icity of complaints. Symptoms and clinical findings may
provide important information to guide treatment of an
underlying illness. In patients with typical GERD symp-
toms, twice-daily high-dose PPI treatment is the most effi-
cient diagnostic approach. GERD is very likely if a positive
treatment response occurs after 1 week, while GERD is un-
likely if there is no response after 4 weeks of PPI treatment.
In patients not responding to PPI, if an endoscopy shows
no pathological findings, other illnesses should be consid-
ered before initiating further gastrointestinal testing.
Panic and anxiety disorders are often missed in clinical
practice [51]. Symptoms such as expressing ‘fear of
dying’, ‘light headedness, dizziness, faintness’, ‘diaphoresis’
and ‘chills or hot flushes’ are associated with anxiety dis-
orders. Screening tests are valuable to rule out panic or
Table 4 Database: PsycINFO <1806 to May Week 4 2012>,
Embase <1974 to 2012 Week 21> (OvidSP)
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further investigation.No. Search Hits
1 (thoracic pain or chest pain or noncardiac chest pain
or non cardiac chest pain or atypical chest pain or
musculoskeletal chest pain or esophageal chest pain
or thoracic spine pain or chest wall).mp. [mp = ti, ab,
hw, tc, id, ot, tm, sh, tn, dm, mf, dv, kw]
44,196
2 exp thorax pain/di [Diagnosis] 2,481
3 exp thorax pain/ 36,580
4 1 or 3 63,756
5 Coronary artery disease or cardiac disease or coronary
heart disease or coronary thrombosis or coronary
occlusion).mp. [mp = ti, ab, hw, tc, id, ot, tm, sh, tn,
dm, mf, dv, kw]
222,468
6 4 not 5 55,961Conclusions
In patients with NCCP, timely diagnostic evaluation
and treatment of the underlying disease is important.
A thorough history of symptoms and clinical examin-
ation findings can inform clinicians which diagnostic
tests are most appropriate. Response to high-dose PPI
treatment can indicate whether GERD is the under-
lying disease and should be considered as an early
test. Panic and anxiety disorders are often not diag-
nosed and should be considered in the differential
diagnosis of chest pain.7 (sensitivity or specificity or diagnostic tests).mp.
[mp = ti, ab, hw, tc, id, ot, tm, sh, tn, dm, mf, dv, kw]
1,162,714
8 2 or 7 1,164,908
9 6 and 8 4,565
10 Limit 9 to human 4,180Appendix 1: Search Strategy May Week 4 2012
In Tables 3 and 4 the detailed search strategy of PubMed,
Web of Knowledge (INSPEC, Biosis/Biological Abstracts,
Web of Science) and OvidSP (Embase, PsycInfo) are given.11 Limit 10 to year = ‘1992-Current’ 3,778
12 Limit 11 to ‘300 adulthood < age 18 years and older > ‘
[Limit not valid in Embase; records were retained]
3,769
13 Limit 12 to adulthood <18+ years > [Limit not valid
in Embase; records were retained]
3,769Biological Abstracts/BIOSIS, INSPEC and Web of Science
(Web of Knowledge)
Topic = (‘thoracic pain’ OR ‘chest pain’ OR ‘noncardiac
chest pain’ OR ‘non cardiac chest pain’ OR ‘atypical
chest pain’ OR ‘musculoskeletal chest pain’ OR ‘esopha-
geal chest pain’ OR ‘thoracic spine pain’ OR ‘chest wall’)
AND Topic = (sensitivity OR specificity OR diagnostic
tests) NOT Topic = (coronary artery disease OR cardiac
disease OR coronary heart disease OR coronary throm-
bosis OR coronary occlusion)
Refined by: Topic = (human*)
Timespan = 1992 to 2012.Table 3 Search Strategy May Week 4 2012 (PubMed)
No. Search Hits
1 Search thoracic pain OR chest pain OR noncardiac chest
pain OR non cardiac chest pain OR atypical chest pain
OR musculoskeletal chest pain OR esophageal chest
pain OR thoracic spine pain OR chest wall
96,313
2 Search coronary artery disease OR cardiac disease OR
coronary heart disease OR coronary thrombosis OR
coronary occlusion
929,959
3 Search 1 NOT 2 38,735
4 Search sensitivity OR specificity OR diagnostic tests
OR chest pain/diagnosis
1,301,595
5 Search 3 AND 4 2,736
6 Search 5 NOT 2; Filters: publication date from
1992/01/01; humans
2,177
7 Search 5 NOT 2; Filters: publication date from
1992/01/01; humans; adult: 19+ years
1,432Appendix 2: Set up of the hierarchical Bayesian
models for the summary receiver operating
characteristic (ROC) curves
Model 1: proton pump inhibitor (PPI) studies
Assumption: imperfect reference standard
Prior distributions:
Prior of prevalence (pi) is beta (12, 12), <= > pi in [0.3, 0.7]
Prior of beta is uniform (−0.75, 0.75)
Prior of THETA is uniform (−1.5, 1.5)
Prior of LAMBDA is uniform (−3, 3)
Prior of sigma_alpha is uniform (0, 2)
Prior of sigma_theta is uniform (0, 2)
Prior of S2 (sensitivity of reference test) is:
Study(ies) 1 to 7 beta (172.55, 30.45), <= > S2 in [0.8, 0.9]
Prior of C2 (specificity of reference test) is:
Study(ies) 1 to 7 beta (50.4, 12.6), <= > C2 in [0.7, 0.9]
Model 2: exertional 24 h pH-metry
Assumption: imperfect reference standard
Prior distributions:
Prior of prevalence (pi) is beta (5.2318, 6.0194), <= > pi
in [0.18, 0.75]
Prior of beta is uniform (−0.75, 0.75)
Prior of THETA is uniform (−1.5, 1.5)
Prior of LAMBDA is uniform (−3, 3)
Prior of sigma_alpha is uniform (0, 2)
Prior of sigma_theta is uniform (0, 2)
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Study(ies) 1 to 5 beta (172.55, 30.45), <= > S2 in [0.8, 0.9]
Prior of C2 (specificity of reference test) is:
Study(ies) 1 to 5 beta (50.4, 12.6), <= > C2 in [0.7, 0.9]Appendix 3: Summary of excluded studies during
full-text review
In Table 5 summarizes the studies reviewed in full-text
and excluded from the systematic review. For each study
the reason for exclusion is provided.Table 5 Summary of excluded studies during full-text review
Author Year Design Comments
Aanen 2008 cohort, prospective No diagnostic study. No NCCP. GERD, reproducibility of reflux symptoms only
Abbass 2009 randomised clinical trial No diagnostic study. No NCCP. General pain patients
Achem 1993 retrospective, review Prevalence of nutcracker esophagus in NCCP. For treatment outcome open label trial with
small sample
Achem 1997 randomised, controlled trial No diagnostic study. GERD patients only received PPI
Achem 2000 review article Review article about atypical chest pain
Adams 2001 retrospective review no NCCP. Spiral CT in pulmonary embolism
Adamek 1995 cross-sectional study No reference test. Description of coexistence of motility disorders and pathologic acid
reflux
Aikens 2001 cross-sectional study No diagnostic study, presence of fear in NCCP patients. Correlation of fear with symptoms
Aizawa 1993 cross-sectional study no NCCP, acetylcholine provocation test for coronary arterial spasm
Ajanovic 1999 cross-sectional study no NCCP. Pulmonary embolism
Aksglaede 2003 experimental Experimental. Small sample (n = 5) chest pain.
Alexander 1994 cross-sectional study Prevalence and nature of mental disorders in NCCP and IHD
Amarasiri 2010 cross-sectional study GERD patients not NCCP
Anzai 2000 cross-sectional study No reference test, coronary flow reserve with dopler in patients with no significant
coronary stenosis
Armstrong 1992 review article Review article about atypical chest pain
Arnold 2009 randomised clinical trial No diagnostic study. Treatment outcome
Aufderheide 1996 validation Validation of ACI-TIPI probabilities for MI
Bak 1994 cohort, prospective No diagnostic study. Comparison of prevalence of findings
Balaban 1999 experimental No diagnostic study. Small sample (n = 10)
Baniukiewicz 1997 cross-sectional study No diagnostic study. Description of findings in upper GI studies
Barham 1997 observational No NCCP. Description of presence of esophageal spasm in patients undergoing
upper GI studies
Barki 1996 cohort, prospective No diagnostic study. Description of clinical presentation in painful rip syndrome
Basseri 2011 experimental Experimental. No NCCP. Different techniques swallow studies
Bassotti 1998 cohort, retrospective No NCCP. Nutcracker esophagus and the symptoms and findings investigated.
Bassotti 1992 cohort, prospective No diagnostic study. Prevalence
Beck 1992 cross-sectional study No diagnostic study. Charasteristics of NCCP patients compared to general
pain patients
Belleville 2010 cross-sectional study No diagnostic study. Characteristics of patients with panic disorders in the ER
Berkovich 2000 cohort, retrospective No NCCP
Bernstein 2002 validation GOLDmineR: improvement of a risk model
Berthelot 2005 cohort, retrospective No diagnostic study. Pain referral study after injection
Bjorksten 1999 cross-sectional study No patients, workers with muscoloskeletal complaints
Table 5 Summary of excluded studies during full-text review (Continued)
Blatchford 1999 cross-sectional study No NCCP. Emergency medical admission rates
Borjesson 1998 cross-sectional study Small sample (n = 18), prevalence of esophageal findings
Borjesson 1998 non-randomised controlled
trial
No diagnostic study. Small sample size (n = 20 per group). Intervention = TENS
Bortolotti 2001 experimental No diagnostic study, small sample (n = 9)
Bortolotti 1997 randomised clinical trial No diagnostic study. L-Arginine in patients with NCCP. Small sample (n = 8)
Bovero 1993 cohort, prospective Duplicate of same study Bovero 1993 included in the analysis under different titel
Bovero 1993 cohort, prospective Duplicate of same study Bovero 1993 included in the analysis under different titel
Brims 2010 review article Review article about atypical chest pain
Broekaert 2006 experimental Experimental trial in volunteers (no patients, n = 10)
Brunse 2010 cohort, prospective No diagnostic study. Prevalence
Brusori 2001 cross-sectional study Mixed sample, diagnosis of esophageal dysmotility in fluoroscopy vs. Manometry
Budzynski 2010 cross-sectional study Mixed patients sample with significant and non significant coronary leasons not
responding to PPI treatment
Bruyninckx 2009 cross-sectional study No diagnostic study. GP's reasons for referral
Cameron 2006 case series Case series, selected sample by gastroenterologist. Not all patients had all
investigation. Small samples for each group
Cannon 1994 randomised clinical trial Treatment outcome (imipramine vs. placebo)
Carter 1997 review article Review article about atypical chest pain
Cremonini 2005 review article Systematic Review PPI
Castell 1998 Editorial Editorial
Chambers 1998 observational Small sample size: n = 23, SI in 7 patients not calculated
Cheung 2007 cross-sectional study No diagnostic study. Questionnaire to doctors to see what kind of patients they
see, what diagnostic tests they use and how they treat.
Christenson 2004 cohort, prospective Chest discomfort inappropriately not diagnosed ACS. Different research question
Crichton 1997 experimental Experimental statistical rule out
Cossentino 2012 randomised clinical trial No diagnostic study. Baclofen in gastro-esophageal diseases
Dekel 2003 cohort, retrospective No diagnostic study. Prevalence of esophageal motility disorders.
Dekel 2004 Not randomised, not controlled
trial
PPI trial only 14 patients included (only GERD positive treated)
Deng 2009 cross-sectional study No NCCP. Combination between cardiac ischemia and esophageal spasms
De Vries 2006 cross-sectional study Mixed patient sample with cardiac and non-cardiac chest pain
Dickman 2007 cohort, prospective No diagnostic study. Prevalence of GI findings in NCCP vs. patients with GERD
Disla 1994 cohort, prospective No diagnostic study, prevalence
Domanovits 2002 cross-sectional study Rule out cardiovascular disease. No diagnostic study for NCCP
Ellis 1992 cohort, prospective No diagnostic study. Treatment outcome in patients with esophageal spasm
Elloway 1992 cross-sectional study provocative radionuclide esophagealNo comparison to reference test,
radionuclide esophageal transit (P-RET) investigation, small sample (n = 30)
Elloway 1992 cross-sectional study Same study under different title
Erhardt 2002 Guideline Task force on the management of chest pain
Esayag 2008 retrospective review Pleuritic chest pain. No reference test, description of presentation and outcome
Esler 2001 randomized clinical trial Dissertation, same as following.
Esler 2003 randomized clinical trial Treatment intervention in NCCP. CBT in NCCP seems to reduce chest pain episodes
Fass 1999 cohort, prospective No diagnostic study. Treatment outcome study
Fleischmann 1997 cross-sectional study No NCCP. Echokardiographic findings in acute chest pain and health status
Fletcher 2011 cohort, prospective Sample size: 8 patients with NCCP
Fornari 2008 cohort, retrospective No NCCP. Only nutcracker esophagus investigated
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Fournier 1993 cross-sectional study No NCCP. Ergovine test during coronary angiogram and induction of coronary spasm
Fournier 1993 cross-sectional study Same study under different titles
Foldes 2011 cross-sectional study No comparison of test with reference test. Prevalence of panic disorders
Frobert 1996 cross-sectional study No diagnostic study. Comparison of characteristics between NCCP with positive
treadmill test compared to negative treadmill test.
Gentile 2003 cross-sectional study Patients with pneumococcal pneumonia. No reference test, description of
presentation, microbiological findings and mortality
Gignoux 1993 experimental No diagnostic study, experimental study
Goehler 2011 experimental Simulation model of CT scan
Goodacre 2004 randomized clinical trial No diagnostic study. Comparison of treatments
Gustafsson 1997 non-randomised controlled
trial
Sample size: intravenous edrophonium chloride test in 16 patients
Ha 1998 cross-sectional study No only NCCP. Patients with suspected coronary artery spasm. Ergonovine
provocation test and scintigrafic findings. Small sample (n = 26)
Hamm 2011 Guideline ESC Guidelines
Herbella 2009 cross-sectional study No NCCP. Presentation of GERD patients
Hess 2008 validation Diagnostic accuracy to exclude coronary artery disease
Hillis 2003 observational Correlation of predictors and long term outcome. No diagnostic study
Hick 1992 cohort, retrospective No diagnostic study. Comparison of characteristics
Hirano 2001 cross-sectional study No NCCP. Coronary artery spasm
Ho 2001 cross-sectional study No diagnostic study. Difference between cardiovascular disease and
non-cardiovascular disease
Hobson 2006 experimental Experimental for pain threshold.
Hobson 2006 experimental Same study under different titels
Howarth 2003 cohort, prospective Ischemic heart disease and GERD
Hu 2000 experimental Experimental trial in volunteers
Hughes 2007 cohort, retrospective No diagnostic study. Risk factors for Reflux or NCCP
Hung 2010 review article Review article about atypical chest pain
Ilgen 2011 validation Diagnostic accuracy to exclude coronary artery disease
Jacobs 2007 Guideline executive summary of management patients with ischemic heart disease
Jerlock 2005 qualitative study No diagnostic study. Qualitative study
Johnston 1993 cohort, retrospective No diagnostic study, prevalence
Jones 1999 cross-sectional study Pleuritic chest pain. Review article
Kahrilas 2011 systematic review Systematic Review PPI Trial in NCCP, reference publication for included studies
Kao 1993 cross-sectional study No diagnostic study, prevalence
Karamanolis 2008 experimental Healthy volunteers
Karlson 1994 observational No diagnostic study. Prognosis and outcome after discharge for ER
Ke 1993 cohort, prospective No diagnostic study, prevalence of GERD in NCCP
Keefe 2011 randomised clinical trial No diagnostic study. Coping skills training, sertraline, placebo
Keogh 2004 cross-sectional study No diagnostic study. Presence of various psychological factors in the ER in cardiac
vs. NCCP on cardiac chest pain
Kisley 1997 cohort, prospective No diagnostic study. Prognosis after discharge after first admission with acute
chest pain
Klingerman 2011 cross-sectional study Rule out cardiovascular disease. No diagnostic study for NCCP
Klopocka 2005 cohort, prospective No diagnostic study. Only 24 patients with NCCP
Klopocka 2005 cohort, prospective Same study under different titles
Koop 2005 journal article GERD. No diagnostic study in NCCP
Kumarathurai 2008 cohort, prospective No diagnostic study.
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Kushner 1992 cross-sectional study small sample: n = 27. Presence of panic disorders in relatives.
Lacy 2009 cross-sectional study Prevalence study
Lam 1994 cohort, prospective No diagnostic procedure. Only patients included that chest pain was reproduced
during the investigation
Lanzarini 1994 cross-sectional study Description of findings in dobutamine stress echocardiography in patients with
positive exercise stress test and negative coronar angiography including
ergonovine stress test.
Lauenbjerg 1997 observational No diagnostic study. Long term prognosis in patients with NCCP of various
etiologies
Lee 2011 randomised clinical trial Conference proceeding. No diagnostic study
Lee 2005 cross-sectional study Prevalence study
Lehtola 2010 randomised, controlled trial Treatment outcome (manipulation, acupuncture vs. placebo. No diagnostic study
Lessard 2012 Patients with NCCP with Panic disorders. Two different interventions, no
diagnostic study
Lien 2011 cohort, prospective NCCP not investigated
Lin 2004 cross-sectional study No NCCP. GERD symptoms and underlying conditions. Differences between women
and men
Liu 2006 cross-sectional study No NCCP patients. Correlation analysis between psychological factors and findings
Lopez Gaston 1994 cross-sectional study Only esophageal pain investigated not NCCP
Lopez Gaston 1994 cross-sectional study Same study under different titles
Lopez Gaston 1994 cross-sectional study Same study under different titles
Loten 2009 observational No diagnostic study. Adverse outcome / prognosis of mixed patient population
Lyer 2009 retrospective review Spontaneous pneumomediastinum. Presentation and findings. No diagnostic study
MacPherson 2007 cross-sectional study No diagnostic study. Survey of patients after ER diagnosis NCCP about interest
in acupuncture
Maev 2007 randomised clinical trial Conference proceeding
Maev 2007 randomised clinical trial Same study under different titles
Makk 2000 experimental Experimental study. No diagnostic study. Comparison of acid infusion and cardiac
vs. non-cardiac chest pain. Small sample
Manchikanti 2003 observational No NCCP. Medial branch blocks for musculoskeletal pain
Manterola 2004 cross-sectional study No diagnostic study. Clinical presentation of patients with NCCP
Martina 1997 cross-sectional study All patients presenting in primary care. NCCP not as subgroup investigated
Matthews 2005 Meta-analysis Meta-analysis for PPI-Trial
Mayou 1994 cohort, prospective No diagnostic study. Comparison of NCCP vs. IHD patients
Mayou 2002 cohort, prospective No diagnostic study. One year follow-up in comparison to cardiac chest pain.
Comparison of costs to the CVD patients
Mearin 1998 cohort study, prospective No diagnostic study. Change of habits during manometry
Mehta 1995 experimental No reference test as “true positive” defined.
Mendelson 1997 cohort, prospective Reference test are cancer patients. Comparison of Szintigraphy for the diagnosis
of costochondritis
Mitchell 2006 cross-sectional study Prevalence of risk factors and pretest probability
Miniati 1999 cross-sectional study no NCCP. Pulmonary embolism
Miniati 2001 cross-sectional study no NCCP. Pulmonary embolism
Miniati 2003 cross-sectional study no NCCP. Prediction model for pulmonary embolism
Mujica 2001 cohort, prospective No diagnostic study in patients. Healthy volunteers
Mulero 1999 cross-sectional study Small sample (n = 24). No reference test. Descriptive findings in SPECT
Munk 2008 cohort, prospective No diagnostic study. Risk of death in patients with unexplained chest pain
Nanbu 1997 cross-sectional study Focus on difference between IHD and NCCP patients. Valdity of the medical
interview for patients with NCCP
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Nasr 2010 experimental Experimental study.
Nasr 2010 experimental Same study under different titels
Nellemann 2000 experimental Small sample (n = 5 with chest pain)
Nevitt 1999 secondary analysis of an RCT No NCCP. Vertebral fracture
Nikolic 2010 cross-sectional study No diagnostic study. Comparison of NCCP to IHD patients
Nilsson 2003 cross-sectional study Prevalence of Diagnosis of IHD in primary care.
Okada 1993 cross-sectional study No NCCP. Provocation of myocardial ischemia by hyperventilation
Oliver 1999 cross-sectional study CT in acute non-cardiac chest pain. No reference. Description of diagnoses found.
Pandak 2002 cross-sectional study duplicate of the study included in the analysis
Panju 1996 observational No diagnostic study. Patients prognosis after discharge
Paterson 1993 cohort, prospective exclude, small sample
Paterson 1995 cross-sectional study No diagnostic study. Description of finding in balloon distention NCCP in
comparison to other pain patients
Paterson 1996 cross-sectional study Not enough information to populate a two by two table. Small sample (n = 23)
Porter-Moffitt 2006 cross-sectional study Small sample (Chest pain n = 34). Comparison of findings to other pain diagnosis.
Rasmussen 2009 cohort, prospective No NCCP. Complex regional pain syndrome
Robertson 2008 cross-sectional study Comparison of psychological morbidity in cardiac vs. Non-cardiac chest pain
Rosano 1996 randomised clinical trial No diagnostic study. Treatment of 17-beta-estradiol patches compared to
placebo on NCCP in postmenopausal women
Ratnaike 1993 retrospective review No diagnostic study. Audit for IHD
Rate 1999 experimental healthy volunteers
Rencoret 2006 cross-sectional study No diagnostic study. Prevalence of esophageal disorders in patients with NCCP
compared to other GI diseases
Repasky 2005 validation ED chest pain pathway
Rokkas 1992 cross-sectional study Not enough information to populate the two by two table
Rose 1994 cohort, prospective No diagnostic study. Does esophageal testing prevent persistence of symptoms?
No control group
Rose 1994 cohort, prospective Same study under different titles
Rosengren 2008 Editorial Editorial
Rousset 2011 retrospective review No NCCP. Catammenial pneumothorax and endometriosis-related pneumothorax
Ruigomez 2004 cohort study No diagnostic study. Description of risk factors, incidence and comorbidities
Sakata 1996 cross-sectional study No reference test. Description of homeostasis and fibrinolysis in patients with
coronary artery spasm. Not sure only NCCP patients
Sakamoto 2011 cross-sectional study Acute chest pain, rule out aortic dissection or pulmonary embolism
Salles 2011 cohort, retrospective No diagnostic study: SAPHO syndrome, clinical characteristics.
Sanchis 2008 cross-sectional study clinical risk profile of patients with acute chest pain without ST-segment deviation
or troponin elevation
Scarinci 1994 cohort, prospective No NCCP. Women with GERD clinical presentation
Schima 1992 cohort, prospective Small sample (n = 4 NCCP)
Schima 1992 cohort, prospective Same study under different titles
Schmidt 2002 cross-sectional study No NCCP. General pain patients
Schmulson 2004 review article Review article about atypical chest pain
Shahid 2005 cross-sectional study No diagnostic study. Prensentation of young adults with chest pain
Shapiro 2006 No NCCP patients. Functional heart burn (pH Man normal) vs. NERD
(ph manometry pathologic) incl. psychometric profile).
Sharma 2010 experimental healthy volunteers
Shelby 2009 randomized clinical trial Same sample as 210 and 217. Description of psychological factors at baseline.
Sigurdsson 2009 retrospective review Retrospective analysis of lung biopsy. No NCCP group
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Singh 1993 retrospective review duplicate of the included study
Smith 2000 retrospective review Feasibility study based on records in a chiropractic clinic.
Smout 1992 experimental experimental. Small sample (n = 10)
Sobralske 2005 review article Review article about atypical chest pain
Spencer 2006 observational No NCCP. GI patients long term outcome
Sporer 2007 cross-sectional study Rule out cardiovascular disease. No diagnostic study for NCCP
Stahl 1994 cohort, prospective Small sample (n = 13 NCCP patients)
Steurer 2010 Metaanalysis clinical value of diagnostic instruments to rule out IHD
Stochkendahl 2008 randomised clinical trial Study protocol
Stochkendahl 2012 randomised, controlled trial No diagnostic study. Treatment outcome
Stochkendahl 2012 randomised, controlled trial No diagnostic study. Same study as previous. Treatment outcome 1 year follow-up
Stollman 1997 cross-sectional study Small sample (n = 14 patients)
Taylor 2002 cross-sectional study Rule out strategy cardiovascular patients. No diagnostic study in NCCP
Taniguchi 2009 cross-sectional study Chest pain in asthma. Treatment response to bronchodilatators
Tew 1995 cross-sectional study No diagnostic study. Outcome cardiovascular patients
Tougas 2001 experimental Experimental. Autonomic reaction to acid infusion in NCCP patients (n = 28)
compared to controls
Triadafilopoulos 1997 cohort, prospective GERD patients. Description of spectrum of patients. Only a few with NCCP
Tutuian 2006 cross-sectional study Not enough information to populate a two by two table in NCCP patients with
esophageal spasm
Valdovinos 2004 experimental No reference test. pH Bravo- capsule. Safety, efficacy and experience in 11 patients
Van Kleef 1995 observational No diagnostic study. Intervention success comparison after radiofrequency lesion
of the dorsal root ganglion
Van Peski-
Oosterbaan
1998 cross-sectional study Survey about how people are interested in psychological treatment after
discharge after cardiac unit admission. Mixed patients sample.
van Ravensteijn 2012 systematic review Diagnostic test efficacy in various pain patients
Varia 2000 randomised, controlled trial No diagnostic study. Comparison efficacy Sertraline vs. Placebo.
Vent 2010 journal article dysphagia cause of chest pain
Verdon 2010 observational Chest pain early diagnostic guess accuracy in GP’s
Vermeltfoort 2009 cross-sectional study Mixed patient sample with cardiac and non-cardiac chest pain
Volpicelli 2008 cohort, prospective Pleural sonography for the diagnosis of pulmonary embolism
Wang 2011 cross-sectional study Conference proceeding
Watkins 2011 journal article Diagnosis and management of community-acquired pneumonia
Weiner 2006 journal article Cardiac markers in low-risk patients. No study
Weingarten 1993 cross-sectional study No diagnostic study for NCCP. Reduction of length of stay by complying the
guidelines
White 2011 cross-sectional study no diagnostic study. Prevalence
Wong 2002 cohort, prospective no comparison to a reference test. Descriptive information only.
Wulsin 2002 randomised clinical trial no diagnostic study. Treatment of paroxetine vs. usual care
Yelland 2010 review article Review article about atypical chest pain
Yu 1997 cross-sectional study Not enough information to populate a two by two table for symptom index
and the presence of GERD
Zalar 1995 cross-sectional study Conference proceeding
Zarauza 2003 observational No diagnostic study. Follow-up after discharge
Zheng 2008 cross-sectional study Small sample (n = 27)
Zheng 2008 cross-sectional study Same study under different title
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Intercollegiate Guidelines Network (SIGN) quality
assessment [19]
In Table 6 the study quality assessed by using the
Scottish Intercollegiate Guidelines Network (SIGN)
methodology checklist for diagnostic studies [19] is sum-
marized. Study quality was assessed by two reviewers
independently.Table 6 Summary of the Scottish Intercollegiate Guidelines N
Lead author/study 1.1 1.2 1.3 1.4 1.5 1.6
Dickman [31] WC WC WC WC WC WC
Bautista [32] WC WC WC WC WC WC
Fass [33] WC WC WC WC WC WC
Pandak [34] WC WC WC WC WC WC
Kim [35] WC WC WC WC WC WC
Xia [36] WC WC WC WC WC WC
Kushinir [37] WC WC AA PA WC WC
Lacima [38] WC PA WC WC WC WC
Cooke [39] WC AA WC WC WC WC
Bovero [40] WC PA WC WC WC WC
Romand [41] WC AA WC WC WC WC
Abrahao [42] WC WC WC WC WC WC
Ho [29] WC PA WC WC WC WC
Kim [24] WC WC WC WC WC WC
Hong [25] WC WC WC WC WC WC
Netzer [26] WC AA WC WC WC WC
Mousavi [27] WC WC WC WC WC WC
Singh [28] WC PA WC WC WC WC
Lam [30] WC PA WC WC WC WC
Achem [43] WC WC WC WC WC WC
Demiryoguran [48] WC WC WC WC WC WC
Foldes-Busque [49] WC WC WC WC WC WC
Kujipers [47] WC WC WC WC WC WC
Katerndahl [51] WC AA WC WC WC WC
Fleet [50] WC WC WC WC WC WC
Stochkendahl [44] WC WC WC NA WC WC
Manchikanti [46] WC WC WC WC PA PA
Bosner [45] WC WC WC WC WC WC
1.1: spectrum of patients is representative of patients who will receive the test
the condition correctly; 1.4: period between reference standard and index test
patients receive same reference test regardless of index test results; 1.7: refere
described in detail; 1.9: reference standard described in detail; 1.10: index test
standard results interpreted without knowledge of result index test; 1.12: unint
provided for withdrawals; 2.1: reliability of the conclusion of the study. Risk of
fulfilled. If not fulfilled, the conclusions of the study are very unlikely to alter.
described are unlikely to alter the conclusions. (−), low quality: few or no crite
AA adequately addressed, N/A not applicable, NA not addressed, NR not reported, PAppendix 5: Summary of all tests evaluated
Table 7 provides a detailed description of all tests and
reference tests investigated. Sensitivity, specificity, posi-
tive predictive value (PPV), negative predictive value
(NPV), prevalence, and post test prevalence are given.
Sensitivity calculated by TP/(TP + FN); specificity cal-
culated by TN/(FP + TN). Biomechanical dysfunction
defined as chest pain presumably caused by mechanicaletwork (SIGN) quality assessment [19]
1.7 1.8 1.9 1.10 1.11 1.12 1.13 2.1
WC WC WC WC WC WC N/A ++
WC WC WC WC WC WC N/A ++
WC WC WC WC WC WC WC ++
WC WC WC WC WC PA PA +
WC WC WC WC WC PA PA ++
WC WC WC WC WC WC WC ++
WC WC WC NA NA N/A PA +
WC WC WC NA NA WC WC +
WC WC WC NA NA WC WC +
WC WC WC NA NA WC WC +
WC WC WC NA NA WC WC +
WC WC WC NA NA WC WC ++
WC WC WC NA NA PA WC +
WC WC WC NA NA WC WC ++
WC WC WC NA NA WC WC ++
WC PA WC NA NA WC WC +
WC WC WC NA NA WC WC ++
WC AA WC NA NA WC WC +
WC WC WC NA NA WC WC +
WC AA WC NA NA WC WC +
WC WC WC WC WC WC WC ++
WC WC AA WC NA WC N/A ++
WC WC WC NA NA WC WC ++
WC WC WC WC WC WC WC ++
WC WC WC WC WC WC WC ++
PA WC WC NA NA WC WC +
WC WC WC WC PA PA WC +
WC AA WC WC AA WC WC ++
; 1.2: selection criteria described; 1.3: reference standard is likely to classify
short enough; 1.5: whole sample received verification of diagnosis; 1.6:
nce standard independent of index test; 1.8: execution of index test
interpreted without knowledge of result of reference test; 1.11: reference
erpretable or intermediate results are reported; 1.13: explanation is
bias (2.1) is as follows. (++), high quality: most of the criteria have been
(+), moderate quality: some criteria fulfilled. Criteria not adequately
ria fulfilled. The conclusions are likely to alter.
A poorly addressed, WC well covered.
Table 7 Summary of all tests evaluated
Criteria Evaluated test Reference standard TP FP FN TN Sensitivity Specificity PPV NPV LR+ LR- Prevalence Post-test
+
prevalence
Post-test -
prevalence
Symptoms
Kim et al. [24] NCCP with atypical GERD
symptoms
Endoscopy (LA classification)
and/or 24 h pH-metry (>4%,
pH <4
3 20 5 6 0.38 0.23 0.13 0.55 0.49 2.71 24 13 45
Kim et al. [24] NCCP with typical GERD symptoms Endoscopy (LA classification)
and/or 24 h pH-metry (>4%,
pH <4
11 2 5 6 0.69 0.75 0.85 0.55 2.75 0.42 67 85 45
Mousavi et al.
[27]
NCCP with typical GERD symptoms GERD if two tests positive:
endoscopy (Hentzel-Dent),
Bernstein test, omeprazole
trial
11 5 24 38 0.31 0.88 0.69 0.61 2.70 0.78 45 69 39
Mousavi et al.
[27]
NCCP relieved by antacid GERD if two tests positive:
endoscopy (Hentzel-Dent),
Bernstein test, omeprazole
trial
15 36 20 7 0.43 0.16 0.68 0.64 0.51 3.51 45 29 74
Mousavi et al.
[27]
NCCP and heartburn in history GERD if two tests positive:
endoscopy (Hentzel-Dent),
Bernstein test, omeprazole
trial
14 8 21 35 0.40 0.81 0.64 0.63 2.15 0.74 45 64 38
Mousavi et al.
[27]
NCCP and regurgitation in history GERD if two tests positive:
endoscopy (Hentzel-Dent),
Bernstein test, omeprazole
trial
17 7 18 36 0.49 0.84 0.71 0.67 2.98 0.61 45 71 33
Hong et al.
[25]
NCCP Manometry (Specler 2001
criteria) and/or 24 h pH-metry
(>4% pH <4)
72 114 128 148 0.36 0.56 0.39 0.54 0.83 1.13 43 39 46
Hong et al.
[25]
Control: dysphagia Manometry (Specler 2001
criteria) and/or 24 h pH-metry
(>4% pH <4)
27 26 181 228 0.13 0.90 0.51 0.56 1.27 0.97 45 51 44
Hong et al.
[25]
Control: GERD-typical symptoms Manometry (Specler 2001
criteria) and/or 24 h pH-metry
(>4% pH <4)
53 53 151 205 0.26 0.79 0.50 0.58 1.26 0.93 44 50 42
Hong et al.
[25]
Dysphagia Manometry 16 37 84 325 0.16 0.90 0.30 0.80 1.57 0.94 22 30 21
Hong et al.
[25]
Dysphagia 24 h pH-metry 4 49 63 346 0.06 0.88 0.08 0.85 0.48 1.07 15 8 15
Hong et al.
[25]
Dysphagia Manometry and 24 h pH-
metry
7 46 23 386 0.23 0.89 0.13 0.94 2.19 0.86 7 13 6
Hong et al.
[25]
NCCP Manometry 34 152 63 213 0.35 0.58 0.18 0.77 0.84 1.11 21 18 23
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Table 7 Summary of all tests evaluated (Continued)
Hong et al.
[25]
NCCP 24 h pH-metry 29 157 43 233 0.40 0.60 0.16 0.60 1.00 1.00 16 16 16
Hong et al.
[25]
NCCP Manometry and 24 h pH-
metry
9 177 22 254 0.29 0.59 0.05 0.92 0.71 1.20 7 5 8
Hong et al.
[25]
GERD-typical symptoms Manometry 19 87 81 275 0.19 0.76 0.18 0.77 0.79 1.07 22 18 23
Hong et al.
[25]
GERD-typical symptoms 24 h pH-metry 23 83 49 307 0.32 0.79 0.22 0.86 1.50 0.86 16 22 14
Hong et al.
[25]
GERD-typical symptoms Manometry and 24 h pH-
metry
11 95 20 336 0.35 0.78 0.10 0.94 1.61 0.83 7 10 6
Netzer et al.
[26]
NCCP Manometry and/or 24 h pH-
metry (>10.5% pH <4)
31 14 223 35 0.12 0.71 0.69 0.14 0.43 1.23 84 69 86
Netzer et al.
[26]
Control: GERD-typical symptoms Manometry and/or 24 h pH-
metry (>10.5% pH <4)
127 16 127 33 0.50 0.67 0.89 0.21 1.53 0.74 84 89 79
Netzer et al.
[26]
Control: dysphagia Manometry and/or 24 h pH-
metry (>10.5% pH <4)
48 8 206 41 0.19 0.84 0.86 0.17 1.16 0.97 84 86 83
Netzer et al.
[26]
GERD-typical symptoms 24 h pH-metry 115 28 49 111 0.70 0.80 0.80 0.69 3.48 0.37 54 80 31
Netzer et al.
[26]
Dysphagia 24 h pH-metry 6 50 158 89 0.04 0.64 0.11 0.36 0.10 1.50 54 11 64
Netzer et al.
[26]
NCCP 24 h pH-metry 24 21 140 118 0.15 0.85 0.53 0.46 0.97 1.01 54 53 54
PPI trial
Dickman et al.
[31]
Rabeprazole 20 mg twice a day for
1 week SIS ≥50%
Endoscopy (Hentzel-Dent
grades) and/or 24 h pH-metry
(>4.2% pH <4)
12 2 4 17 0.75 0.89 0.86 0.81 7.13 0.28 46 86 19
Dickman et al.
[31]
Placebo for 1 week Endoscopy (Hentzel-Dent
grades) and/or 24 h pH-metry
(>4.2% pH <4)
3 4 13 15 0.19 0.79 0.43 0.54 0.89 1.03 46 43 46
Bautista et al.
[32]
Lansoprazole 60 mg AM, 30 mg PM
for 1 week SIS ≥50%
Endoscopy (Hentzel-Dent
grades) and/or 24 h pH-metry
(>4.2% pH <4)
14 2 4 20 0.78 0.91 0.875 0.833 8.56 0.24 45 88 17
Bautista et al.
[32]
Lansoprazole 60 mg AM, 30 mg PM
for 1 week SIS ≥65%
Endoscopy (Hentzel-Dent
grades) and/or 24 h pH-metry
(>4.2% pH <4)
15 1 3 21 0.83 0.95 0.93 0.88 18.33 0.17 45 94 13
Bautista et al.
[32]
Placebo for 1 week Endoscopy (Hentzel-Dent
grades) and/or 24 h pH-metry
(>4.2% pH <4)
4 8 14 14 0.22 0.64 0.33 0.50 0.61 1.22 45 33 50
Fass et al. [33] Omeprazole 40 mg AM, 20 mg PM
for 1 week SIS ≥50%
Endoscopy (Hentzel-Dent
grades) and/or 24 h pH-metry
(>4.2% pH <4)
18 2 5 12 0.78 0.86 0.90 0.71 5.48 0.25 62 90 29
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Table 7 Summary of all tests evaluated (Continued)
Fass et al. [33] Placebo for 1 week Endoscopy (Hentzel-Dent
grades) and/or 24 h pH-metry
(>4.2% pH <4)
5 1 18 13 0.22 0.93 0.83 0.42 3.04 0.84 62 83 58
Pandak et al.
[34]
Omeprazole 40 mg twice a day for
2 weeks SIS ≥50%
Endoscopy and/or 24 h pH-
metry (>4.2% pH <4)
18 6 2 12 0.90 0.67 0.75 0.86 2.70 0.15 53 75 14
Pandak et al.
[34]
Placebo for 2 weeks SIS ≥50% Endoscopy and/or 24 h pH-
metry (>4.2% pH <4)
1 3 19 15 0.05 0.83 0.25 0.44 0.30 1.14 53 25 56
Kim et al. [35] NCCP GERD-related (TP) vs NCCP
non-GERD-related (TN): rabeprazole
for 1 week SIS ≥50%
Endoscopy (LA classification)
and/or 24 h pH-metry (>4.0
pH <4)
8 6 8 20 0.50 0.77 0.57 0.71 2.17 0.65 38 57 29
Kim et al. [35] NCCP GERD-related (TP) vs NCCP
non-GERD-related (TN): rabeprazole
for 2 weeks SIS ≥50%
Endoscopy (LA classification)
and/or 24 h pH-metry (>4.0
pH <4)
13 7 3 19 0.81 0.73 0.65 0.86 3.02 0.26 38 65 14
Xia et al. [36] Lansoprazole 30 mg once a day for
4 weeks SIS ≥50%
24 h pH-metry (De Meester
pH <4, 7.5 s)
11 8 1 16 0.92 0.67 0.58 0.94 2.75 0.13 33 58 6
Xia et al. [36] Placebo for 4 weeks SIS ≥50% 24 h pH-metry (De Meester
pH <4, 7.5 s)
4 7 8 13 0.33 0.65 0.36 0.62 0.95 1.03 38 36 38
Kushnir et al.
[37]
High-degree response on PPI (not
specified)
24 pH-metry (≥4%, pH <4) 40 18 12 28 0.77 0.61 0.69 0.70 1.97 0.38 53 69 30
Kushnir et al.
[37]
High-degree response on PPI Positive Ghillibert probability
estimate (GPE)
21 37 5 35 0.81 0.49 0.36 0.88 1.57 0.40 27 36 12
Kushnir et al.
[37]
High-degree response on PPI Association of chest pain with
pH <4 in reference standard:
SI ≥50%
19 39 6 34 0.76 0.47 0.33 0.85 1.42 0.52 26 33 15
Kushnir et al.
[37]
High-degree response on PPI 24 h pH-metry and positive
GPE
15 43 2 38 0.88 0.47 0.26 0.95 1.66 0.25 17 26 5
Kushnir et al.
[37]
High-degree response on PPI 24 h pH-metry and SI ≥50% 16 42 2 38 0.89 0.48 0.28 0.95 1.69 0.23 18 28 5
Kushnir et al.
[37]
High-degree response on PPI 24 h pH-metry and SI ≥50%
and positive GPE
14 44 1 39 0.93 0.47 0.24 0.98 1.76 0.14 15 24 2
Symptom index
Singh et al.
[28]
Association of chest pain with pH
<4 in reference standard: SI ≥50%
Endoscopy and/or 24 h pH-
metry (De Meester >5.5% pH
<4)
19 38 15 81 0.56 0.68 0.33 0.84 1.75 0.65 22 33 16
Singh et al.
[28]
Association of chest pain with pH
<4 in reference standard: SI ≥25%
Endoscopy and/or 24 h pH-
metry (De Meester >5.5% pH
<4)
23 59 11 60 0.68 0.50 0.28 0.85 1.36 0.64 22 28 15
Singh et al.
[28]
Association of chest pain with pH
<4 in reference standard: SI ≥75%
Endoscopy and/or 24 h pH-
metry (De Meester >5.5% pH
<4)
8 5 26 114 0.24 0.96 0.62 0.81 5.60 0.80 22 62 19
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Table 7 Summary of all tests evaluated (Continued)
Singh et al.
[28]
Association of heartburn with pH
<4 in reference standard: Symptom
Index (SI) ≥50%
Endoscopy and/or 24 h pH-
metry (De Meester >5.5% pH
<4)
40 32 3 78 0.93 0.71 0.56 0.96 3.20 0.10 28 56 4
Singh et al.
[28]
Association of heartburn with pH
<4 in reference standard: SI ≥25%
Endoscopy and/or 24 h pH-
metry (De Meester >5.5% pH
<4)
41 40 2 70 0.95 0.64 0.51 0.97 .62 0.07 28 51 3
Singh et al.
[28]
Association of heartburn with pH
<4 in reference standard: SI ≥75%
Endoscopy and/or 24 h pH-
metry (De Meester >5.5% pH
<4)
25 25 9 94 0.74 0.79 0.50 0.91 .50 0.34 28 58 12
Ho et al. [29] Association of chest pain with pH
<4 in reference standard: SI >50%
24 h pH-metry (>4% pH <4,
4 s)
3 9 11 38 0.21 0.81 0.25 0.78 .12 0.97 23 25 22
Lam et al. [30] Association of chest pain with pH
<4 in reference standard: SI ≥75%
24 h pH-metry (execution in
acute stage)
13 0 15 13 0.46 1.00 1.00 0.48 3.03 0.54 68 97 54
Others
Lacima et al.
[38]
24 h-manometry (pH <4) Manometry during hospital
stay
18 24 18 30 0.50 0.56 0.43 0.56 .13 0.90 40 43 38
Provocation test
Cooke et al.
[39]
NCCP during exertional pH-metry 24 h pH-metry (5.5% pH <4
for 10 s)
4 0 15 31 0.21 1.00 1.00 0.67 4.40 0.79 38 90 33
Cooke et al.
[39]
Control group: CVD with angina:
exertional pH-metry
24 h pH-metry (5.5% pH <4
for 10 s)
1 1 2 12 0.33 0.92 0.50 0.86 .33 0.72 19 50 14
Bovero et al.
[40]
NCCP with normal ECG during
exertional pH-metry
24 h pH-metry (De Meester
criteria: >4.5% pH <4))
17 1 29 20 0.37 0.95 0.94 0.41 .76 0.66 69 94 59
Bovero et al.
[40]
NCCP at rest: NCCP with normal
ECG during exertional pH-metry
24 h pH-metry (De Meester
criteria: >4.5% pH <4))
11 1 23 11 0.32 0.92 0.92 0.32 .88 0.74 74 92 68
Bovero et al.
[40]
NCCP exertion/mixed: NCCP with
normal ECG during exertional pH-
metry
24 h pH-metry (De Meester
criteria: >4.5% pH <4))
6 0 6 9 0.50 1.00 1.00 0.60 0.00 0.50 57 93 40
Bovero et al.
[40]
24 h pH-metry (De Meester criteria:
>4.5% pH <4))
NCCP with normal ECG
during exertional pH-metry
17 29 1 20 0.94 0.41 0.37 0.95 .60 0.14 27 37 5
Bovero et al.
[40]
24 h pH-metry (De Meester criteria:
>4.5% pH <4))
NCCP at rest: NCCP with
normal ECG during exertional
pH-metry
11 23 1 11 0.92 0.32 0.32 0.92 .36 0.26 26 32 8
Romand et al.
[41]
NCCP: pH <4 for 10 s during
exertional pH-metry
24 h pH-metry (De Meester
criteria: >4.5% pH <4))
7 14 3 19 0.70 0.58 0.33 0.86 .65 0.52 23 33 14
Abrahao et al.
[42]
NCCP reproducible during balloon
distension
Endoscopy (Savary-Miller)
and/or manometry and/or
pH-metry (De Meester criteria:
>4.5% pH <4
14 1 21 4 0.40 0.80 0.93 0.16 .00 0.75 88 93 84
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Table 7 Summary of all tests evaluated (Continued)
Abrahao et al.
[42]
NCCP reproducible during Tensilon
test
Endoscopy (Savary-Miller)
and/or manometry and/or
pH-metry (De Meester criteria:
>4.5% pH <4
6 2 29 3 0.17 0.60 0.75 0.09 0.43 1.38 88 75 91
Abrahao et al.
[42]
NCCP reproducible during
Bernstein test
Endoscopy (Savary-Miller)
and/or manometry and/or
pH-metry (De Meester criteria:
>4.5% pH <4
9 1 26 4 0.26 0.80 0.90 0.13 1.29 0.93 88 90 87
Abrahao et al.
[42]
Tensilon and Bernstein Test and
balloon distension (+ if 1 test +)
Endoscopy (Savary-Miller)
and/or manometry and/or
pH-metry (De Meester criteria:
>4.5% pH <4
20 3 15 2 0.57 0.40 0.87 0.12 0.95 1.07 88 87 88
Abrahao et al.
[42]
NCCP reproducible during Tensilon
test
Endoscopy (Savary-Miller)
and/or pH-metry (De Meester
criteria: >4.5% pH <4
6 2 26 6 0.19 0.75 0.75 0.19 0.75 1.08 80 75 81
Abrahao et al.
[42]
NCCP reproducible during
Bernstein test
Endoscopy (Savary-Miller)
and/or pH-metry (De Meester
criteria: >4.5% pH <4
8 2 24 6 0.25 0.75 0.80 0.20 1.00 1.00 80 80 80
Abrahao et al.
[42]
NCCP reproducible during balloon
distension
Endoscopy (Savary-Miller)
and/or pH-metry (De Meester
criteria: >4.5% pH <4
13 2 19 6 0.41 0.75 0.87 0.24 1.63 0.79 80 87 76
Abrahao et al.
[42]
Tensilon and Bernstein Test and
balloon distension (+ if 1 test +)
Endoscopy (Savary-Miller)
and/or pH-metry (De Meester
criteria: >4.5% pH <4
18 5 14 3 0.56 0.38 0.78 0.18 0.90 1.17 80 78 82
Ho et al. [29] NCCP reproducible during
Bernstein test
Endoscopy 4 7 3 56 0.57 0.89 0.36 0.95 5.14 0.48 10 36 5
Eosinophilia
Achem et al.
[43]
Current GERD symptoms Esophageal biopsies 10 26 14 121 0.42 0.82 0.28 0.90 2.36 0.71 14 28 10
Achem et al.
[43]
Male gender or current GERD
symptoms
Esophageal biopsies 18 69 6 78 0.75 0.53 0.21 0.93 1.60 0.47 14 21 7
Achem et al.
[43]
Male gender or any abnormal EoE
endoscopic finding
Esophageal biopsies 23 79 1 68 0.96 0.46 0.23 0.99 1.78 0.09 14 23 1
Achem et al.
[43]
Current GERD symptoms or any
abnormal EoE endoscopic finding
Esophageal biopsies 20 63 4 84 0.83 0.57 0.24 0.96 1.94 0.29 14 24 5
Musculoskeletal
Stochkendahl
et al. [44]
Biomechanical dysfunction Standardized examination
protocol
112 120 0 70 1.00 0.37 0.48 1.00 1.58 0.00 37 48 0
Stochkendahl
et al. [44]
≥3 of 5 overall palpation findings Standardized examination
protocol
111 124 1 66 0.99 0.35 0.47 0.99 1.52 0.03 37 47 1
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Table 7 Summary of all tests evaluated (Continued)
Bosner et al.
[45]
Chest wall symptom (CWS) score:
localized muscle tension, stinging
pain, pain reproducible by
palpation, absence of cough, cut-
off test negative 0 to 1 points
Interdisciplinary consensus:
cardiologist, GP, research
associate (based on reviewed
baseline, follow-up data)
506 318 59 329 0.90 0.51 0.66 0.82 1.82 0.20 47 61 15
Bosner et al.
[45]
CWS score: localized muscle
tension, stinging pain, pain
reproducible by palpation, absence
of cough, cut-off test negative 0 to
2 points
Interdisciplinary consensus 357 135 208 512 0.63 0.79 0.76 0.67 3.02 0.47 47 72 29
Stochkendahl
et al. [44]
Anterior chest wall tenderness Standardized examination
protocol
110 134 2 56 0.98 0.29 0.45 0.97 1.39 0.06 37 45 3
Stochkendahl
et al. [44]
Angina pectoris (uncertain or
negative)
Standardized examination
protocol
109 147 3 43 0.97 0.23 0.43 0.94 1.26 0.12 37 43 7
Stochkendahl
et al. [44]
Pain worse on movement of torso Standardized examination
protocol
32 16 80 174 0.29 0.92 0.67 0.69 3.39 0.78 37 67 32
Bosner et al.
[45]
Pain worse with movement Interdisciplinary consensus 221 119 344 528 0.39 0.82 0.65 0.61 2.13 0.75 47 65 40
Stochkendahl
et al. [44]
Positive/possible belief in pain
origin from muscle/joints
Standardized examination
protocol
108 156 4 34 0.96 0.18 0.41 0.90 1.17 0.20 37 41 11
Stochkendahl
et al. [44]
Pain relief on pain medication Standardized examination
protocol
25 13 87 177 0.22 0.93 0.66 0.67 3.26 0.83 37 66 33
Bosner et al.
[45]
Pain reproducible by palpation Interdisciplinary consensus 351 193 214 454 0.62 0.70 0.68 0.64 2.08 0.54 47 65 32
Stochkendahl
et al. [44]
Paraspinal tenderness Standardized examination
protocol
90 112 22 78 0.80 0.41 0.45 0.78 1.36 0.48 37 45 22
Bosner et al.
[45]
Localized muscle tension Interdisciplinary consensus 346 164 219 483 0.61 0.75 0.71 0.66 2.41 0.52 47 68 32
Stochkendahl
et al. [44]
Chest pain present now Standardized examination
protocol
92 116 20 74 0.82 0.39 0.44 0.79 1.35 0.46 37 44 21
Bosner et al.
[45]
Pain now Interdisciplinary consensus 328 327 237 320 0.58 0.49 0.50 0.57 1.15 0.85 47 50 43
Stochkendahl
et al. [44]
Pain debut not during a meal Standardized examination
protocol
109 168 3 22 0.97 0.12 0.39 0.88 1.10 0.23 37 39 12
Stochkendahl
et al. [44]
Sharp pain Standardized examination
protocol
39 35 73 155 0.35 0.82 0.53 0.68 1.89 0.80 37 53 32
Bosner et al.
[45]
Stinging pain Interdisciplinary consensus 299 184 266 463 0.53 0.72 0.62 0.63 1.87 0.66 47 62 37
Stochkendahl
et al. [44]
Hard physical exercise at least once
a week
Standardized examination
protocol
42 60 70 130 0.38 0.68 0.41 0.65 1.19 0.91 37 41 35
Stochkendahl
et al. [44]
Pain not provoked during a meal Standardized examination
protocol
109 170 3 20 0.97 0.11 0.39 0.87 1.09 0.25 37 39 13
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Table 7 Summary of all tests evaluated (Continued)
Stochkendahl
et al. [44]
Not sudden debut Standardized examination
protocol
53 31 59 159 0.47 0.84 0.63 0.73 2.90 0.63 37 63 27
Bosner et al.
[45]
Pain >24 h Interdisciplinary consensus 158 139 407 508 0.28 0.79 0.53 0.56 1.30 0.92 47 54 45
Stochkendahl
et al. [44]
Age ≤49 years old Standardized examination
protocol
67 54 45 136 0.60 0.72 0.55 0.75 2.10 0.56 37 55 25
Bosner et al.
[45]
Pain mostly at noon time Interdisciplinary consensus 13 30 552 617 0.02 0.95 0.31 0.53 0.50 1.02 47 31 48
Bosner et al.
[45]
Cough Interdisciplinary consensus 31 129 534 518 0.06 0.80 0.19 0.49 0.28 1.18 47 20 51
Bosner et al.
[45]
Known IHD Interdisciplinary consensus 56 122 509 525 0.10 0.81 0.32 0.51 0.52 1.11 47 32 50
Bosner et al.
[45]
Pain worse with breathing Interdisciplinary consensus 138 123 427 524 0.24 0.81 0.53 0.55 1.28 0.93 47 53 45
Manchikanti et
al. [46]
Chronic thoracic pain: lidocaine
injection
Bupivacaine injection 22 14 _ _ 0.61 _
Psychiatric
Kuijpers et al.
[47]
Anxiety subscale of the Hospital
Anxiety and Depression Scale
(HADS-A score, cut-off ≥8)
Diagnosis Anxiety disorders
(Mini International
Neuropsychiatric Interview
(gold standard))
195 71 3 75 0.98 0.51 0.73 0.96 2.03 0.03 58 73 4
Demiryoguran
et al. [48]
Palpitation Anxiety disorder: HADS-A
score (cut-off ≥10)
18 25 31 80 0.37 0.76 0.42 0.72 1.54 0.83 31 41 27
Demiryoguran
et al. [48]
Fear of dying Anxiety disorder: HADS-A
score (cut-off ≥10)
11 6 38 102 0.22 0.94 0.65 0.73 4.04 0.82 31 65 27
Demiryoguran
et al. [48]
Light-headedness, dizziness,
faintness
Anxiety disorder: HADS-A
score (cut-off ≥10)
11 8 38 100 0.22 0.93 0.58 0.73 3.03 0.84 31 58 28
Demiryoguran
et al. [48]
Chills or hot flushes Anxiety disorder: HADS-A
score (cut-off ≥10)
11 5 38 103 0.22 0.95 0.69 0.73 4.85 0.81 31 69 27
Demiryoguran
et al. [48]
Shortness of breath Anxiety disorder: HADS-A
score (cut-off ≥10)
13 22 36 86 0.27 0.80 0.37 0.71 1.30 0.92 31 37 29
Demiryoguran
et al. [48]
Nausea or gastric discomfort Anxiety disorder: HADS-A
score (cut-off ≥10)
9 10 40 98 0.18 0.91 0.47 0.71 1.98 0.90 31 47 29
Demiryoguran
et al. [48]
Diaphoresis Anxiety disorder: HADS-A
score (cut-off ≥10)
19 12 30 96 0.39 0.89 0.61 0.76 3.49 0.69 31 61 24
Foldes-Busque
et al. [49]
The Panic Screening Score
(derivation population)
Panic disorder diagnosis
(structured Anxiety Disorders
Interview Schedule for
Diagnostic and Statistical
Manual of Mental Disorders,
fourth edition DSM-IV (ADIS-
IV))
53 19 31 98 0.63 0.84 0.74 0.76 3.89 0.44 42 74 24
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Table 7 Summary of all tests evaluated (Continued)
Foldes-Busque
et al. [49]
The Panic Screening Score
(validation population)
Panic disorder diagnosis
(structured ADIS-IV)
69 27 61 148 0.53 0.85 0.72 0.71 3.44 0.55 43 72 29
Katerndahl et
al. [51]
GP diagnosis of panic disorder Panic disorder (structured
clinical Interview of Diagnostic
and Statistical Manual of
Mental Disorders, based on
DSM-III-R)
2 2 26 21 0.07 0.91 0.50 0.45 0.82 1.02 55 50 55
Fleet et al. [50] Panic disorder diagnosis: formula
including Agoraphobia Cognitions
QA, Mobility Inventory for
Agoraphobia, Zone 12 Dermatome
Pain Map, Sensory McGill Pain QA,
Gender, Zone 25 (Validation
population)
Panic Disorder (ADIS-R
structured interview by
psychologist)
32 41 17 122 0.65 0.75 0.44 0.88 2.60 0.46 23 44 12
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atic structures of the spine and chest wall established by
means of joint-play and/or end-play palpation.
24-h pH-metry: 24-h pH monitoring measures with a
single sensor located above the lower esophageal sphinc-
ter (LES) a reflux event and the association of the reflux
event with symptoms can also be ascertained from the
tracing; manometry: esophageal manometry measures
mean pressure of the lower esophageal sphincter and
any degree of hypomotility and dysmotility in the
esophagus.
LR+, positive likelihood ratio calculated sensitivity/1 -
specificity; LR-, negative likelihood ratio calculated 1 -
sensitivity/specificity; diagnostic test accuracy. Very
good: LR + >10, LR- <0.1; good: LR + 5 to 10, LR- 0.1 to
0.2; fair: LR + 2 to 5, LR- 0.2 to 0.5; poor: LR + 1 to 2,
LR- 0.5 to 1.
Reference tests are as follows. Endoscopic classifica-
tion: LA classification: grade A, ≥1 mucosal break
≤5 mm, that does not extend between the tops of two
mucosal folds; grade B, ≥1 mucosal break >5 mm long
that does not extend between the tops of two mucosal
folds; grade C, ≥1 mucosal break that is continuous be-
tween the tops of two or more mucosal folds but which
involves <75% of the circumference; grade D, ≥1 muco-
sal break which involves at least 75% of the esophageal
circumference [52]. Savary-Miller System: grade I, single
or isolated erosive lesion(s) affecting only one longitu-
dinal fold; grade II, multiple erosive lesions, non-
circumferential, affecting more than one longitudinal
fold, with or without confluence; grade III, circumferen-
tial erosive lesions; grade IV, chronic lesions: ulcer(s),
stricture(s) and/or short esophagus. Alone or associated
with lesions of grades 1 to 3; grade V, columnar epithe-
lium in continuity with the Z line, non-circular, star-
shaped, or circumferential. Alone or associated with le-
sions of grades 1 to 4 [53]. Hentzel-Dent grades: grade
0, no mucosal abnormalities; grade 1, no macroscopic le-
sions but erythema, hyperemia, or mucosal friability;
grade 2, superficial erosions involving <10% of mucosal
surface of the last 5 cm of esophageal squamous mucosa;
grade 3, superficial erosions or ulceration involving 10%
to 50% of the mucosal surface of the last 5 cm of
esophageal squamous mucosa; grade 4, deep peptide ul-
ceration anywhere in the esophagus or confluent erosion
of >50% of the mucosal surface of the last 5 cm of
esophageal squamous mucosa [54]. pH-metry: De Mee-
ster criteria: (1) total number of reflux episodes; (2)
number of reflux episodes with pH <4 for more than
5 minutes; (3) duration of the longest episode; (4) per-
centage total time pH <4; (5) percentage upright time
pH <4; and 6) percentage recumbent time pH <4. [55].
Manometry: Spechler criteria: diagnosis of ineffective
esophageal motility, nutcracker esophagus, spasm,achalasia based on: basal lower esophageal sphincter
pressure, relaxation, wave progression, distal wave amp-
litude [56].
ACQ Agoraphobia Cognitions Questionnaire, ADIS-R
structured interview by psychologist, recommended
interview protocol for panic research, CVD cardiovascu-
lar disease, DSM-IV (ADIS-IV) Anxiety Disorders Inter-
view Schedule, GERD gastroesophageal reflux disease,
GP general practitioner, GPE Ghillibert probability esti-
mate (sum of partial probabilities for exact numbers of
reflux associated symptoms within the context of the
total number of symptoms), HDR high-degree response,
EoE eosinophilic esophagitis (typical abnormal EoE
endoscopic findings (rings or furrows)), IHD ischemic
heart disease, McGill sensory McGill Pain Questionnaire
sensory, MIA Mobility Inventory for Agoraphobia, MINI
Mini International Neuropsychiatric Interview (gold
standard for anxiety disorders), NPV negative predictive
value, PPV positive predictive value, SI symptom index
(calculated as the proportion of chest pain symptoms
(pH <4) divided by the number of chest pain episodes
recorded, expressed as a percentage), SIS symptom index
score (calculated by adding the reported daily severity
(mild = 1; moderate = 2; severe = 3; and disabling = 4)
multiplied by the reported daily frequency values during
each week).
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